var title_f0_51_816="Proper lifting knees bent";
var content_f0_51_816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proper lifting mechanics: Knees bent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sharon Alzner, MPT.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_816=[""].join("\n");
var outline_f0_51_816=null;
var title_f0_51_817="Control of gastric motility";
var content_f0_51_817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55162&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Control of gastric motility",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The motor function of the gut is controlled at three main levels: extrinsic neural control (vagal and sympathetic); intrinsic neural control; and excitability of smooth muscle cells controlled by transmitters.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Camilleri M, Prather CM. In: Sleisenger and Fordtran's Gastrointestinal Disease, 6th ed, Feldman M, Scharschmidt BF, Sleisenger MH (Eds), W.B. Saunders, Philadelphia 1998. p.572.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_817=[""].join("\n");
var outline_f0_51_817=null;
var title_f0_51_818="Patient information: Seborrheic keratosis (The Basics)";
var content_f0_51_818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83445\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/26/15791\">",
"         Seborrheic keratosis",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/8/26756\">",
"          Seborrheic keratosis on dark skin",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?41/46/42722\">",
"         Patient information: Melanoma skin cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/26/26018\">",
"         Patient information: Skin cancer (non-melanoma) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?28/6/28772\">",
"         Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/16/25857\">",
"         Patient information: Skin warts (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Seborrheic keratosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/seborrheic-keratosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H109628876\">",
"      <span class=\"h1\">",
"       What is seborrheic keratosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Seborrheic keratosis (called &ldquo;SK&rdquo; here) is a condition that causes growths on the skin. It usually happens in people older than 50, but younger people also get it. The growths can look like something that was stuck on the skin (",
"      <a class=\"graphic graphic_picture graphicRef83279 \" href=\"UTD.htm?15/26/15791\">",
"       picture 1",
"      </a>",
"      ). They can be light tan, brown, or black (",
"      <a class=\"graphic graphic_picture graphicRef83280 \" href=\"UTD.htm?26/8/26756\">",
"       picture 2",
"      </a>",
"      ). It is usually easy to see where normal skin ends and the growth starts. The growths sometimes look scaly. &nbsp;",
"     </p>",
"     <p>",
"      A person can have 1 or many of these growths. If there are more than 1, they are called &ldquo;seborrheic keratoses.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109628891\">",
"      <span class=\"h1\">",
"       What are the symptoms of seborrheic keratosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The growths in SK often do not cause any symptoms, but they sometimes itch. They are most common on certain parts of the body. These include the:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trunk &ndash; Chest, belly, and back",
"       </li>",
"       <li>",
"        Arms",
"       </li>",
"       <li>",
"        Face",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109628906\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;SK is common in older people. It is not skin cancer. But some people who get SK also get skin cancer. If you notice any new growths on your skin, ask your doctor or nurse to check them. He or she can make sure they are not cancer or treat them if they are. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109628921\">",
"      <span class=\"h1\">",
"       Is there a test for seborrheic keratosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is no 1 test. The doctor or nurse will do an exam and check your skin. He or she can usually tell if you have SK by looking at any skin changes and touching them. &nbsp;",
"     </p>",
"     <p>",
"      If the doctor is not sure whether SK is causing the skin changes, you will have a test called a &ldquo;biopsy.&rdquo; During a biopsy, a doctor takes a small sample of the SK or takes off the whole growth. Then another doctor looks at the tissue under a microscope to check for skin cancer.",
"     </p>",
"     <p>",
"      The doctor can also do a test called &ldquo;dermoscopy.&rdquo; In this test, he or she looks at the skin with a small microscope that has a light on it. The doctor holds this over the area with skin changes. The microscope and light help the doctor see under the skin. It can help show if a spot is SK or something else.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109628938\">",
"      <span class=\"h1\">",
"       How is seborrheic keratosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with SK do not need treatment. But if the growths bother you or look bad, a doctor or nurse can usually take them off with:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Liquid nitrogen &ndash; This is a special liquid that gets very cold. It can leave an area of lighter skin where the SK was.",
"       </li>",
"       <li>",
"        A scalpel or other small tool &ndash; The doctor or nurse can take off the SK after numbing the skin. He or she might freeze the SK with liquid nitrogen and then take it off.",
"       </li>",
"       <li>",
"        Electricity - The doctor can use electricity to burn away the SK. He or she might take off the SK first and then use electricity to get rid of abnormal tissue under it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H109628953\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/26/26018?source=see_link\">",
"       Patient information: Skin cancer (non-melanoma) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/46/42722?source=see_link\">",
"       Patient information: Melanoma skin cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/16/25857?source=see_link\">",
"       Patient information: Skin warts (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=see_link\">",
"       Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?0/51/818?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83445 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_818=[""].join("\n");
var outline_f0_51_818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109628876\">",
"      What is seborrheic keratosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109628891\">",
"      What are the symptoms of seborrheic keratosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109628906\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109628921\">",
"      Is there a test for seborrheic keratosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109628938\">",
"      How is seborrheic keratosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109628953\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83445\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/26/15791\">",
"      Seborrheic keratosis",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/8/26756\">",
"       Seborrheic keratosis on dark skin",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/46/42722?source=related_link\">",
"      Patient information: Melanoma skin cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/6/28772?source=related_link\">",
"      Patient information: Melanoma treatment; localized melanoma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/26/26018?source=related_link\">",
"      Patient information: Skin cancer (non-melanoma) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/16/25857?source=related_link\">",
"      Patient information: Skin warts (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_51_819="Lupus arthritis swan neck";
var content_f0_51_819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F78325%7ERHEUM%2F65248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F78325%7ERHEUM%2F65248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lupus arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient with long-standing lupus has developed subluxation at the MCP joints and swan neck deformities of her fingers. These deformities are reducible (probably being due to lax tendons) and x-rays reveal no erosions or cysts, both of which differentiate these findings from those in rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter H Schur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Deforming lupus arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe hand deformities in a 75-year-old woman with lupus for more than 20 years. Such hand abnormalities are very rare.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter H Schur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_819=[""].join("\n");
var outline_f0_51_819=null;
var title_f0_51_820="Bupivacaine: Patient drug information";
var content_f0_51_820=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bupivacaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     see \"Bupivacaine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/17/43285?source=see_link\">",
"     see \"Bupivacaine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bupivacaine Spinal;",
"     </li>",
"     <li>",
"      Marcaine&reg;;",
"     </li>",
"     <li>",
"      Marcaine&reg; Spinal;",
"     </li>",
"     <li>",
"      Sensorcaine&reg;;",
"     </li>",
"     <li>",
"      Sensorcaine&reg;-MPF;",
"     </li>",
"     <li>",
"      Sensorcaine&reg;-MPF Spinal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Marcaine&reg;;",
"     </li>",
"     <li>",
"      Sensorcaine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10025867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700555",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use the 0.75% during labor. Unsafe side effects may happen. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691415",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to numb an area of the skin before care.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701660",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bupivacaine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfite allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat while your mouth feels numb. You may bite your tongue.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor will give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696006",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11931 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-3E1552308A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_820=[""].join("\n");
var outline_f0_51_820=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142923\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142924\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025867\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025869\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025868\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025873\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025874\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025876\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025871\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025872\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025877\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025878\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=related_link\">",
"      Bupivacaine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/17/43285?source=related_link\">",
"      Bupivacaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_51_821="Orbital venous drainage";
var content_f0_51_821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61214&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Venous drainage of the orbit",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The diagram demonstrates the communication between ethmoidal sinuses, the orbit, and the cavernous sinus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_821=[""].join("\n");
var outline_f0_51_821=null;
var title_f0_51_822="Mixed type2 CPAM";
var content_f0_51_822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71008&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Mixed Type II CPAM at 21 weeks of gestation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 441px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial (A) and sagittal (B) ultrasound images of the chest demonstrate a large right chest mass containing multiple macro and microcysts displacing the heart to the left (arrow) and everting the diaphragm inferiorly. Axial (C) MR image demonstrates marked deviation of the heart to the left (arrow). Coronal (D) MR image demonstrates minimal residual normal lung in the left upper lobe (arrow). No systemic feeding vessel and no hydrops appreciated. CVR was 2.4, consistent with high risk for hydrops.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dorothy I Bulas, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_822=[""].join("\n");
var outline_f0_51_822=null;
var title_f0_51_823="Alcoholic steatohepatitis and cirrhosis II - low power";
var content_f0_51_823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Alcoholic steatohepatitis and cirrhosis in a 35-year-old woman (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This section demonstrates more scarring and advanced cirrhosis than in the other sections from the same patient. There was more sampling variation in this biopsy than is typically seen in alcoholic liver disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_823=[""].join("\n");
var outline_f0_51_823=null;
var title_f0_51_824="Amitriptyline and perphenazine: Drug information";
var content_f0_51_824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Amitriptyline and perphenazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/40/35461?source=see_link\">",
"    see \"Amitriptyline and perphenazine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Levazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F133944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Tricyclic (Tertiary Amine);",
"     </li>",
"     <li>",
"      Antipsychotic Agent, Typical, Phenothiazine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F133932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Depression and anxiety:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: One tablet (amitriptyline 25 mg/perphenazine 2 mg or amitriptyline 25 mg/perphenazine 4 mg) 3-4 times/day",
"     <b>",
"      or",
"     </b>",
"     1 tablet (amitriptyline 50 mg/perphenazine 4 mg) 2 times/day; initial therapeutic response may be observed after several days or upwards of a few weeks or longer (maximum daily dose: amitriptyline 200 mg/perphenazine 16 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: Smallest dose necessary for symptom relief; usually 1 tablet (amitriptyline 25 mg/perphenazine 2 mg or amitriptyline 25 mg/perphenazine 4 mg) 2-4 times/day",
"     <b>",
"      or",
"     </b>",
"     1 tablet (amitriptyline 50 mg/perphenazine 4 mg) 2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Schizophrenia and depression:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Initial: Two tablets (amitriptyline 25 mg/perphenazine 4 mg) 3 times/day; if necessary, a fourth dose may be given at bedtime; initial therapeutic response may be observed after several days or upwards of a few weeks or longer (maximum daily dose: amitriptyline 200 mg/perphenazine 16 mg) (maximum: 64 mg/day of perphenazine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance: Smallest dose necessary for symptom relief; usually 1 tablet (amitriptyline 25 mg/perphenazine 2 mg or amitriptyline 25 mg/perphenazine 4 mg) 2-4 times/day",
"     <b>",
"      or",
"     </b>",
"     1 tablet (amitriptyline 50 mg/perphenazine 4 mg) 2 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F133933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: One tablet (amitriptyline 10 mg/perphenazine 4 mg) 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13361720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F133934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; no dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-10: Amitriptyline hydrochloride 10 mg and perphenazine 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-10: Amitriptyline hydrochloride 10 mg and perphenazine 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-25: Amitriptyline hydrochloride 25 mg and perphenazine 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-25: Amitriptyline hydrochloride 25 mg and perphenazine 4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-50: Amitriptyline hydrochloride 50 mg and perphenazine 4 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088622.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088622.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F133919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of patients with moderate-to-severe anxiety and/or agitation and depression; schizophrenia with depressive symptoms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13930066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high [moderate for SIADH]; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F133942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F133922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to amitriptyline, perphenazine, or any component of the formulation (cross-sensitivity with other phenothiazines may exist); bone marrow depression; use with or within 14 days of MAO inhibitors; CNS depression (due to barbiturate, alcohol, narcotic, analgesic, or antihistamine use); during the acute recovery phase of MI",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F133906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;  Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Amitriptyline is not FDA-approved for use in children &lt;12 years of age; this combination is not FDA approved for use in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. Relative to other neuroleptics, perphenazine has a low potency of cholinergic blockade and relative to other antidepressants amitriptyline has a high potential for cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias: Check blood counts periodically and discontinue at first signs of blood dyscrasias; use is contraindicated in patients with bone marrow suppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of pneumonia (ie, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extrapyramidal symptoms: May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperprolactinemia: Perphenazine use is associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use of perphenazine may be associated with NMS; monitor for mental status changes, fever, muscle rigidity, and/or autonomic instability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Perphenazine may cause pigmentary retinopathy, and lenticular and corneal deposits, particularly with prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: Both agents may cause orthostatic hypotension (risk is very high relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: Both agents may cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; SIADH and hyponatremia: Has been associated with the development of SIADH and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur with perphenazine use; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use both agents with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk of conduction abnormalities with this agent is high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. This combination is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use amitriptyline with caution in patients with diabetes mellitus; may alter glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use both agents with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      This combination is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; condition may be exacerbated by cholinergic blockade.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Use perphenazine with caution in patients with Parkinson's disease; they may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use both agents with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use both agents with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiemetic effects: Perphenazine may mask toxicity of other drugs or conditions (eg, intestinal obstruction, Reye's syndrome, brain tumor) due to antiemetic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of amitriptyline in this age group due to its potent anticholinergic and sedative properties, and potential to cause orthostatic hypotension. In addition, may also cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults  (Beers Criteria). Increased risk for developing tardive dyskinesia from perphenazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Poor metabolizers: Use with caution in patients with reduced  functional alleles of CYP2D6. Poor metabolizers may have higher plasma concentrations at usual doses, increasing risk for adverse reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Recommended to discontinue several days prior to elective surgery. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F133939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Antipsychotic Agents (Phenothiazines) may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). Specifically, this may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. Antidepressants (Serotonin Reuptake Inhibitor/Antagonist) may enhance the hypotensive effect of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antimalarial Agents: May increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): May diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Antipsychotic Agents (Phenothiazines) may enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Amitriptyline may enhance the arrhythmogenic effect of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Antidepressants (Tricyclic, Tertiary Amine) may enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F133926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (due to increased sedation).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12586220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12586221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Perphenazine-Amitriptyline Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-10 mg (100): $64.37",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-25 mg (100): $81.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-10 mg (100): $72.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-25 mg (100): $89.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-50 mg (100): $147.39",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F133914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; lipid profile, fasting blood glucose/Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     ; BMI, weight; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms (EPS), suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F133924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Mutabon (IT);",
"     </li>",
"     <li>",
"      Mutabon A (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Mutabon D (AE, AR, BH, CN, CY, EG, ID, IL, IQ, IR, JO, KW, LB, LY, OM, PY, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Mutabon F (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Mutabon M (AE, BH, CY, EG, ID, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Mutabon-A (BB, BM, BS, BZ, GY, JM, NL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Mutabon-D (BB, BM, BS, BZ, GY, JM, NL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Mutabon-F (BB, BM, BS, BZ, GY, JM, NL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Mutabon-M (BB, BM, BS, BZ, GY, JM, NL, PR, SR, TT);",
"     </li>",
"     <li>",
"      Polybon (TH);",
"     </li>",
"     <li>",
"      Triptafen (GB)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F133905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Amitriptyline increases the synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibition of their reuptake by the presynaptic neuronal membrane.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Perphenazine is a piperazine phenothiazine antipsychotic which blocks postsynaptic mesolimbic dopaminergic receptors in the brain; exhibits alpha-adrenergic blocking effect and depresses the release of hypothalamic and hypophyseal hormones.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F133921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/51/824/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boakes AJ, Laurence DR, Teoh PC, et al, &ldquo;Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1973, 1(849):311-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gill SS, Bronskill SE, Normand SL, et al, &ldquo;Antipsychotic Drug Use and Mortality in Older Adults With Dementia,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2007, 146(11):775-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/51/824/abstract-text/17548409/pubmed\" id=\"17548409\" target=\"_blank\">",
"        17548409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/51/824/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larochelle P, Hamet P, and Enjalbert M, &ldquo;Responses to Tyramine and Norepinephrine After Imipramine and Trazodone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(1):24-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/51/824/abstract-text/376211/pubmed\" id=\"376211\" target=\"_blank\">",
"        376211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitchell JR, &ldquo;Guanethidine and Related Agents. III Antagonism by Drugs Which Inhibit the Norepinephrine Pump in Man,&rdquo;",
"      <i>",
"       J Clin Invest",
"      </i>",
"      , 1970, 49(8):1596-604.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/51/824/abstract-text/5431666/pubmed\" id=\"5431666\" target=\"_blank\">",
"        5431666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/51/824/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rundegren J, van Dijken J, M&ouml;rnstad H, et al, &ldquo;Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,&rdquo;",
"      <i>",
"       Swed Dent J",
"      </i>",
"      , 1985, 9(2):55-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/51/824/abstract-text/3925584/pubmed\" id=\"3925584\" target=\"_blank\">",
"        3925584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schneeweiss S, Setoguchi S, Brookhart A, et al, &ldquo;Risk of Death Associated With the Use of Conventional Versus Atypical Antipsychotic Drugs Among Elderly Patients,&rdquo;",
"      <i>",
"       CMAJ",
"      </i>",
"      , 2007, 176(5): 627-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/51/824/abstract-text/17325327/pubmed\" id=\"17325327\" target=\"_blank\">",
"        17325327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Svedmyr N, &ldquo;The Influence of a Tricyclic Antidepressive Agent (Protriptyline) on Some of the Circulatory Effects of Noradrenaline and Adrenalin in Man,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 1968, 7(1):77-84.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8607 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-EBC78AF0D7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_824=[""].join("\n");
var outline_f0_51_824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708613\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133929\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133944\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133932\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133933\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13361720\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133934\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133917\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133902\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874548\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133919\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13930066\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133942\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133922\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133906\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133939\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133910\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133926\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586220\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12586221\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524331\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133914\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133924\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133905\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133921\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8607\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8607|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/40/35461?source=related_link\">",
"      Amitriptyline and perphenazine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_51_825="Variegate porphyria";
var content_f0_51_825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Variegate porphyria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/51/825/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/51/825/contributors\">",
"     Ashwani K Singal, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/51/825/contributors\">",
"     Karl E Anderson, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/51/825/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/51/825/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/51/825/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/51/825/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/51/825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H660084\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variegate porphyria (VP) is an autosomal dominant genetic disorder of porphyrin metabolism due to deficient activity of the mitochondrial enzyme protoporphyrinogen oxidase (PPO), the seventh enzyme in the heme biosynthetic pathway (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    ). The disease is termed &ldquo;variegate&rdquo; because it can cause acute neurological manifestations, as in the other acute hepatic porphyrias, chronic blistering lesions on sun-exposed areas of the skin, as in most cutaneous porphyrias, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VP has also been referred to as porphyria variegata, South African genetic porphyria, mixed porphyria (an obsolete term also applied to hereditary coproporphyria [HCP]), protocoproporphyria, and porphyria cutanea tarda hereditaria (which likely included some cases of familial porphyria cutanea tarda [PCT]) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. The disease has also been termed the Royal malady based on poorly-founded speculation that nonspecific symptoms in King George III of England, including mental symptoms, abdominal pain, and dark urine, were due to this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The other porphyric disorders are discussed elsewhere in UpToDate. An overview of the porphyrias is also available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660092\">",
"    <span class=\"h1\">",
"     HISTORY, PREVALENCE, AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;VP may have been first described in 1937 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/6\">",
"     6",
"    </a>",
"    ]. Extensive genealogical studies in South Africa contributed significantly to our understanding of this disease and indeed to human genetics [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/7\">",
"     7",
"    </a>",
"    ]. Evidence has been provided that the disease was carried from Holland by a man or woman who were married in South Africa in 1688. The prevalence of VP is high in South Africans of Dutch descent because this population remained quite isolated and expanded greatly for many decades [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. This is now a well-known example of genetic drift or the founder effect, with perhaps as many at 30,000 individuals in that country carrying the R59W mutation of the PPO gene [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VP occurs worldwide, but its prevalence is not accurately known because many carriers of PPO mutations remain asymptomatic. In most countries, VP is less commonly recognized than acute intermittent porphyria (AIP) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/4,12\">",
"     4,12",
"    </a>",
"    ], although AIP and VP may be equally prevalent in Finland and Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The prevalence has been estimated to be 1.3 per 100,000 in Finland [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/13\">",
"     13",
"    </a>",
"    ] and 0.3 per 100,000 in Europe generally [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6523550\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;VP results from a deficiency of the mitochondrial enzyme protoporphyrin oxidase (PPO) that is inherited as an autosomal dominant trait [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/16\">",
"     16",
"    </a>",
"    ]. Enzymatic activity is approximately 50 percent of normal in all tissues and mitochondria-containing cells that have been examined, including lymphocytes and cultured fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PPO has a molecular weight of 51,000 Da and consists of 477 amino acids. The PPO gene contains 13 exons and is localized to chromosome 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/19\">",
"     19",
"    </a>",
"    ]. VP is genetically heterogeneous, with more than 140 different mutations identified [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. In South Africa about 95 percent of the cases are due to the R59W missense mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/11\">",
"     11",
"    </a>",
"    ]. PPO mutations in VP generally express little or no enzymatic activity. Accordingly, residual enzyme activity is due to the normal allele that is trans to the mutant allele. Although some mutations are reported to cause a milder phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/21\">",
"     21",
"    </a>",
"    ], genotype-phenotype correlations are less evident in larger studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Very rare homozygous cases of VP, in which a PPO mutation is inherited from each parent, manifest cutaneous photosensitivity and severe neurological manifestations beginning in childhood. At least one of the mutant alleles in the homozygous disease must express some enzyme activity. Interestingly, acute attacks are seldom described in homozygous cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PPO oxidizes protoporphyrinogen to protoporphyrin with removal of six protons (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    ). As a result of decreased activity of PPO, protoporphyrinogen accumulates within hepatocytes and is mostly auto-oxidized to protoporphyrin before excretion in the bile and feces.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous manifestations of VP are associated with elevations of plasma porphyrins, indicating that excess porphyrins are transported in plasma from the liver to the skin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link&amp;anchor=H19#H19\">",
"       \"Porphyrias: An overview\", section on 'Blistering cutaneous porphyrias'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The neurovisceral symptoms in this and other acute porphyrias are likely related to accumulation of a heme pathway intermediate such as delta-aminolevulinic acid (ALA) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/2,24\">",
"       2,24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link&amp;anchor=H5#H5\">",
"       \"Etiology and pathogenesis of acute intermittent porphyria\", section on 'Mechanism for neurological dysfunction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increases in ALA and porphobilinogen (PBG) may result from inhibition of hepatic porphobilinogen deaminase (PBGD) by protoporphyrinogen IX and coproporphyrinogen III, which accumulate in the liver in VP [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/25\">",
"       25",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Elevation of coproporphyrin III may be explained by the close association of PPO with coproporphyrinogen oxidase (CPO) in the mitochondrial membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24936245\">",
"    <span class=\"h2\">",
"     Inciting events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain drugs and steroid hormones (especially progesterone) may exacerbate VP and other acute porphyrias because they induce hepatic delta-aminolevulinic acid synthetase-1 (ALAS1), the rate-limiting enzyme for heme biosynthesis in the liver, and cytochrome P450 enzymes (CYPs). Both the ALAS1 gene and certain hepatic CYP genes respond to inducing chemicals and interact with the pregnane X receptor (PXR) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/26\">",
"     26",
"    </a>",
"    ]. With an inherited deficiency of PPO, induction of hepatic ALAS1 is enhanced and leads to accumulation of protoporphyrinogen IX, which becomes auto-oxidized to protoporphyrin IX. The adjacent locations of PPO and CPO in the mitochondrial membrane may account for accumulation of coproporphyrinogen III, which is auto-oxidized to coproporphyrin III. Protoporphyrinogen IX and coproporphyrinogen III inhibition of PBG deaminase may provide an explanation for the accumulation of ALA and PBG especially during acute exacerbations of VP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660099\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;VP may present with acute neurovisceral manifestations (ie, acute attacks (",
"    <a class=\"graphic graphic_table graphicRef56856 \" href=\"UTD.htm?26/3/26683\">",
"     table 1",
"    </a>",
"    )) that are identical to those in AIP and other acute hepatic porphyrias, or as chronic blistering skin lesions that are identical to those seen in porphyria cutanea tarda (PCT). These distinct features usually occur separately in time [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations and diagnosis of acute intermittent porphyria\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As in AIP, acute attacks may be precipitated by certain drugs, endogenous progesterone, and metabolic stress due to concurrent medical conditions or surgery, and may be life threatening. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link&amp;anchor=H6#H6\">",
"       \"Etiology and pathogenesis of acute intermittent porphyria\", section on 'Exacerbating factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurovisceral manifestations may be precipitated by caloric restriction in an effort to lose weight [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/27\">",
"       27",
"      </a>",
"      ], gastric bypass surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/28,29\">",
"       28,29",
"      </a>",
"      ], or concurrent medical conditions such as metastatic cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/28-30\">",
"       28-30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pregnancy is usually well tolerated, but in some patients is associated with more frequent attacks.",
"     </li>",
"     <li>",
"      Risks of chronic systemic arterial hypertension, renal disease, and hepatocellular carcinoma are increased, as in AIP [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical manifestations and diagnosis of acute intermittent porphyria\", section on 'Long term effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Blistering skin lesions are chronic, and much more common in VP than in HCP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In recent decades, with more extensive biochemical and genetic testing, at least in some countries, such as South Africa and Finland, more cases have been diagnosed when asymptomatic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In South Africa, only 10 percent of individuals diagnosed with VP were asymptomatic in 1980, 38 percent in 1997, and an estimated 60 percent more recently [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,3,4\">",
"       1,3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As in AIP, the frequency of acute attacks in patients with VP has decreased in the past several decades, probably due to less frequent use of harmful drugs (eg, barbiturates and sulfonamides) in clinical practice, and greater attention to early diagnosis and prevention.",
"     </li>",
"     <li>",
"      The proportion of patients with acute attacks, reported to be 34 percent in South Africa and 32 percent in Finland before 1980, has decreased to 9 percent in South Africa and 4 percent in Finland, and was reported to be 8.7 percent in Italy in 2009 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,3,4,13,31\">",
"       1,3,4,13,31",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Cutaneous symptoms are now reported in about 40 to 50 percent of cases; their prevalence has decreased less than the acute neurological symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660106\">",
"    <span class=\"h2\">",
"     Neurovisceral symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;VP is an autosomal dominant condition with low penetrance, and only about 10 percent of patients with VP develop an acute attack in their lifetime [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1\">",
"     1",
"    </a>",
"    ]. Although VP is much more common than AIP in South Africa, most acute attacks of porphyria in that country are due to AIP. This indicates that, even though attacks of both diseases have decreased in recent decades, those due to AIP are more common, more severe, and occur at a younger age, on average [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,3,4,13\">",
"     1,3,4,13",
"    </a>",
"    ]. Nonetheless, acute attacks in VP are potentially life-threatening if not recognized promptly and managed appropriately.",
"   </p>",
"   <p>",
"    Attacks of VP are reported to occur equally in males and females, whereas AIP attacks are considerably more common in females [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. The prevalence of precipitating factors may also differ, with attacks of AIP more commonly occurring in the absence of identified factors. Drugs and alcohol are more commonly reported as precipitating factors in VP, and infection, pregnancy, fasting, and the menstrual cycle more common in AIP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. These differences are of interest, but not highly relevant to diagnosis and management of individual VP patients.",
"   </p>",
"   <p>",
"    Acute attacks of neurovisceral symptoms are identical to those seen in AIP, but may on average be somewhat milder [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,3,4,13\">",
"     1,3,4,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal pain, usually severe and diffuse, is associated with little or no tenderness or other peritoneal signs. Extremity, back, and chest pain may be severe.",
"     </li>",
"     <li>",
"      Nausea, vomiting, constipation, and distension due to ileus, and bladder dysfunction with urinary retention are common.",
"     </li>",
"     <li>",
"      Hypertension and tachycardia may reflect autonomic neuropathy or adrenergic stimulation.",
"     </li>",
"     <li>",
"      Renal infarction and bowel intussusception have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyponatremia is common in more severe attacks, and is often due to the syndrome of inappropriate ADH secretion (SIADH).",
"     </li>",
"     <li>",
"      As in AIP, seizures may result from hyponatremia or be a neurological manifestation of porphyria [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1\">",
"       1",
"      </a>",
"      ]. Agitation and acute psychotic features are common.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24936309\">",
"    <span class=\"h3\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral neuropathy, which is primarily motor, occurs especially in more prolonged attacks, and can lead to flaccid paralysis of all extremities and respiratory failure. Weakness usually begins proximally, and may not be detected until it has progressed distally. Severe extremity pain reflects sensory involvement as well. As in the other acute porphyrias, accumulation of a neuropathic substance, perhaps delta-aminolevulinic acid (ALA), is believed to lead to axonal damage, although heme deficiency in neuronal tissue is an alternative mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology and pathogenesis of acute intermittent porphyria\", section on 'Mechanism for neurological dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660113\">",
"    <span class=\"h2\">",
"     Cutaneous symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic blistering and increased fragility of sun-exposed areas of the skin are common in VP during adult life [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. Dorsal aspects of the hands and fingers are most commonly affected, and less commonly the forearms, face, ears, and neck. Scarring and pigment changes of these areas, and hypertrichosis of the face and forearms may occur (",
"    <a class=\"graphic graphic_picture graphicRef83390 \" href=\"UTD.htm?29/26/30116\">",
"     picture 1",
"    </a>",
"    ). These manifestations, which are identical to those seen in porphyria cutanea tarda (PCT), are due to porphyrins transported in plasma from the liver to the skin, where they are photoactivated by long wave UV light with release of tissue-damaging activated oxygen species. Microscopy may show PAS-positive thickening of vascular walls in the dermis with IgG deposition and reduplication of the basal lamina [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cutaneous symptoms may be more common in South Africa where there are longer periods of sun exposure than in northern European countries such as Finland [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,3,4,13\">",
"     1,3,4,13",
"    </a>",
"    ]. They may become manifest in VP patients with hepatobiliary disease, pregnancy, or with oral contraceptive use [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/35\">",
"     35",
"    </a>",
"    ]. Oral contraceptives may act in part by impairing hepatobiliary excretion of porphyrins. In some cases VP has been associated with celiac disease and dermatitis herpetiformis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660120\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for hepatocellular carcinoma is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/38-40\">",
"     38-40",
"    </a>",
"    ], and patients may develop chronic renal failure. It has been suggested that patients with VP have an increased risk of gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660134\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS AND DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6524394\">",
"    <span class=\"h2\">",
"     Biochemical testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical testing is essential for diagnosis of this and other porphyrias, and molecular testing is increasingly important for diagnostic confirmation and for screening family members who may be asymptomatic carriers of the familial PPO mutation. It is important to differentiate PCT, which is effectively treated by phlebotomy or low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    , from VP and other porphyrias that do not respond to such treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elevations in urinary ALA and PBG are expected during acute attacks (",
"      <a class=\"graphic graphic_algorithm graphicRef61709 \" href=\"UTD.htm?26/12/26831\">",
"       algorithm 1",
"      </a>",
"      ). Such elevations are less marked and more transient in VP (and HCP) than in AIP. A kit for demonstration of a substantial PBG elevation in a spot urine sample is recommended for rapid diagnosis of acute porphyrias (AIP, HCP, or VP) as a cause of acute symptoms. Measurement of total urinary porphyrins is also recommended, since porphyrin elevations persist longer in VP than do elevations in ALA and PBG, keeping in mind that urinary porphyrin elevations are much less specific than elevations in PBG [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/2,42\">",
"       2,42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      VP is readily differentiated from AIP and HCP by biochemical testing [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/2,42\">",
"       2,42",
"      </a>",
"      ]. Fractionation of urinary porphyrins is usually not informative, since uroporphyrin and PBG are often concurrently elevated in AIP, HCP or VP, although coproporphyrin increases may be especially prominent in VP and HCP. Plasma and fecal porphyrin determinations are most useful in distinguishing these conditions (",
"      <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Plasma porphyrins are increased in VP, with a distinctive fluorescence peak at approximately 626 to 628 nm at neutral pH that distinguishes VP from all other porphyrias (",
"      <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/43\">",
"       43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Fecal porphyrins are increased, with a predominance of both coproporphyrin III and protoporphyrin IX. In HCP, plasma porphyrins are usually not increased (and skin lesions are relatively uncommon), and fecal porphyrins are markedly elevated with a predominance of coproporphyrin III that is distinctive.",
"     </li>",
"     <li>",
"      Normal plasma and urinary porphyrins exclude VP and other porphyrias as causes of blistering skin lesions.",
"     </li>",
"     <li>",
"      As with AIP and HCP, chronic mild increases in liver function tests, especially transaminases, may be seen in patients with persistent elevations of ALA, PBG, and porphyrins.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6524401\">",
"    <span class=\"h2\">",
"     Enzymatic and DNA testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assay of PPO activity in cells that have mitochondria, such as fibroblasts and lymphocytes, are useful for confirming a diagnosis of VP but are not widely available [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/25,44\">",
"     25,44",
"    </a>",
"    ]. All cases confirmed by biochemical methods should undergo DNA testing to identify the inherited PPO mutation. This provides further diagnostic confirmation and enables other family members who are carriers of the same mutation and at risk for the disease to be reliably identified. In most countries, each VP family will likely have a different mutation, whereas in South Africa almost all VP patients have the highly prevalent R59W missense mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/11\">",
"     11",
"    </a>",
"    ]. Plasma fluorescence scanning and measurement of PPO activity are useful for detecting family members who have inherited VP, but are less sensitive than DNA studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/42,45\">",
"     42,45",
"    </a>",
"    ]. Mutation analysis is not appropriate for initial diagnosis of VP in either acutely ill patients or those with chronic skin lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660142\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6524408\">",
"    <span class=\"h2\">",
"     Treatment of the acute attack",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24936436\">",
"    <span class=\"h3\">",
"     Establishing the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of VP (or another type of acute porphyria) must be established as certainly as possible before treatment is initiated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a patient with an established diagnosis of VP (see above) and prior attacks, clinical evaluation should determine whether the current presentation is similar to previous attacks and that another cause of abdominal pain or other symptoms is not evident.",
"     </li>",
"     <li>",
"      When acute porphyria is suspected for the first time, porphobilinogen (PBG) should be measured in a spot urine sample and shown to be elevated in order to confirm the diagnosis of one of the acute porphyrias.",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"       hemin",
"      </a>",
"      can lower levels of porphyrin precursors and porphyrins. Therefore, if treatment is to be initiated on clinical grounds before laboratory results are available, spot samples of urine, plasma, and feces should be collected before treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24936443\">",
"    <span class=\"h3\">",
"     Initial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute attacks in VP are treated with glucose loading or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    , with results similar to those seen in patients with acute attacks in the three other hepatic porphyrias (ALA dehydratase porphyria, acute intermittent porphyria, hereditary coproporphyria) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attacks of acute porphyria that are accompanied by severe features, such as pain requiring narcotic analgesics, vomiting, hyponatremia, seizures, or motor neuropathy should be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"       hemin",
"      </a>",
"      . Hemin dosing is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H5#H5\">",
"       \"Management of acute intermittent porphyria\", section on 'Intravenous hemin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Attacks that are less severe can be treated with intravenous or even oral glucose loading. Dosing is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H4#H4\">",
"       \"Management of acute intermittent porphyria\", section on 'Carbohydrate loading'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Potentially harmful drugs, such as barbiturates, sulfonamide antibiotics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/61/6102?source=see_link\">",
"       griseofulvin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , anticonvulsants (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ), alcohol, ergot alkaloids and progestins should be discontinued if at all possible [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/46\">",
"       46",
"      </a>",
"      ]. The table lists many of the drugs that are known to be unsafe or safe in the acute porphyrias (",
"      <a class=\"graphic graphic_table graphicRef57422 \" href=\"UTD.htm?42/6/43116\">",
"       table 3",
"      </a>",
"      ). More complete and up-to-date information is available at the websites of the",
"      <a class=\"external\" href=\"file://www.porphyriafoundation.com/\">",
"       American Porphyria Foundation",
"      </a>",
"      and the",
"      <a class=\"external\" href=\"file://www.porphyria-europe.com/\">",
"       European Porphyria Network",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Other precipitating factors, such as inadequate intake of calories and carbohydrate, metabolic stress due to another illness, or luteal phase increases in endogenous progesterone should be recognized and addressed [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24936450\">",
"    <span class=\"h3\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following supportive care measures should be undertaken during the acute attack:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe attacks are best managed in an intensive care setting to provide monitoring and treatment for imbalances in fluids and electrolytes and to monitor respiratory function by spirometry [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Since pain from an acute attack is usually severe, a narcotic analgesic such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      is generally required.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       Meperidine (pethidine)",
"      </a>",
"      should be avoided since it may lower the seizure threshold [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phenothiazine such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       prochlorperazine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"       promethazine",
"      </a>",
"      is useful for treating nausea and vomiting as well as agitation and restlessness.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"       Ondansetron",
"      </a>",
"      and related drugs are effective for nausea, whereas",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      is contraindicated [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tachycardia and hypertension can be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      if symptomatic or severe.",
"     </li>",
"     <li>",
"      A laxative can be given for constipation, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"       loperamide",
"      </a>",
"      for diarrhea [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other precipitating factors, including infections and nutritional inadequacies, should be identified and treated appropriately [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/2,24\">",
"       2,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Termination of pregnancy is rarely, if ever, indicated for an acute attack of porphyria.",
"     </li>",
"     <li>",
"      Especially after repeated attacks, some patients may develop chronic pain, depression, or other psychiatric problems, and there is risk for suicide. Therefore these manifestations must be recognized and managed appropriately [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24936608\">",
"    <span class=\"h2\">",
"     Treatment of cutaneous manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24936770\">",
"    <span class=\"h3\">",
"     Acute and chronic care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic VP should wear protective clothing to avoid exposure to sunlight. Sunscreens that block long-wave ultraviolet light, or opaque sunscreens containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"     zinc oxide",
"    </a>",
"    or titanium oxide that also block visible light, may be somewhat effective [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1,49\">",
"     1,49",
"    </a>",
"    ]. Affected areas should be kept clean and skin infections treated with antibiotics. Topical steroids should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24936777\">",
"    <span class=\"h3\">",
"     Other treatment issues",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contraceptive steroids are sometimes implicated in VP patients who develop cutaneous manifestations (see above) and should be discontinued if possible.",
"     </li>",
"     <li>",
"      Skin lesions in VP do not respond to short term treatments such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"       hemin",
"      </a>",
"      or glucose loading.",
"     </li>",
"     <li>",
"      The skin lesions may be painful and require oral analgesics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , narcotic analgesics).",
"     </li>",
"     <li>",
"      Although the skin manifestations of VP and PCT are identical, the underlying pathophysiology in these hepatic porphyrias is different. Therefore, repeated phlebotomy to reduce hepatic iron and low dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      to remove accumulated hepatic porphyrins, which are effective in PCT, are not effective in VP.",
"     </li>",
"     <li>",
"      &beta;-Carotene, which can reduce the acute photosensitivity of EPP, is of little benefit in other cutaneous porphyrias, including VP [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/50-52\">",
"       50-52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"       Oral activated charcoal",
"      </a>",
"      has been beneficial in some cases of CEP [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/50\">",
"       50",
"      </a>",
"      ], but has paradoxically worsened skin manifestations of VP [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24936429\">",
"    <span class=\"h2\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute intermittent porphyria who become refractory to treatment, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    , may respond well to liver transplantation, or to combined liver and kidney transplantation if renal failure has developed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/47\">",
"     47",
"    </a>",
"    ]. However, outcomes are poor in patients who are paralyzed from extensive motor neuropathy. Accordingly, transplantation should also be effective in refractory cases of VP, although experience is limited. One patient in whom the diagnosis of VP was suggested but not firmly established underwent successful liver transplantation for cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A mouse model in which a PPO gene is replaced by the human R59W mutant gene has been developed to study the pathophysiology of VP and to test new therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660165\">",
"    <span class=\"h2\">",
"     Prevention of future attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although recurrent attacks are less common in VP than in AIP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/56\">",
"     56",
"    </a>",
"    ], factors that have contributed to past acute attacks or might precipitate future attacks should be identified and addressed. Harmful drugs should be avoided whenever possible. Information on safe and harmful drugs is available at the websites of the",
"    <a class=\"external\" href=\"file://www.porphyriafoundation.com/\">",
"     American Porphyria Foundation",
"    </a>",
"    and the",
"    <a class=\"external\" href=\"file://www.porphyria-europe.com/\">",
"     European Porphyria Network",
"    </a>",
"    . Anesthesia for major surgery should avoid barbiturates and include safe agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/57\">",
"     57",
"    </a>",
"    ]. Rarely, women may develop frequent attacks during the luteal phase of the menstrual cycle, and these can be prevented with a gonadotropin releasing hormone analogue, which is started during the first few days of a cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Unexplained, frequent noncyclic attacks are also rare, and can sometimes be prevented by prophylactic weekly infusions of a single dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6524431\">",
"    <span class=\"h2\">",
"     Screening for long-term complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in other acute porphyrias, risk for hepatocellular carcinoma is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/38,40,61\">",
"     38,40,61",
"    </a>",
"    ]. This warrants screening at least yearly by hepatic imaging after age 50, especially in VP patients with persistent elevations of porphyrins and porphyrin precursors. Chronic renal failure may also occur, and may require long term dialysis or kidney transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660179\">",
"    <span class=\"h2\">",
"     Genetic testing and counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of the PPO mutation in a VP family enables testing of other family members and identification of latent gene carriers who are at risk to develop clinical manifestations of VP. Latent carriers are advised to avoid factors that can exacerbate acute porphyrias, although they are at lower risk than those who have previously had symptoms. Amniocentesis to obtain fetal cells for DNA studies is not recommended because the prognosis of offspring who inherit a PPO mutation is generally favorable, and therefore termination of pregnancy is not often considered [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H660186\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients usually recover from acute attacks and the long term prognosis of patients with VP is good. Even advanced neuropathy may improve over months or years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/1\">",
"     1",
"    </a>",
"    ]. However, some patients have recurrent attacks in the absence of known exacerbating factors, and pain and other symptoms sometimes become chronic and difficult to manage. Depression and other chronic psychiatric manifestations may occur, but are usually not attributable to VP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/50,56\">",
"     50,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long term outcome in most VP patients who have had symptoms is favorable. Morbidity and mortality in VP have decreased in recent decades, presumably due to improved management of overt cases of VP and diagnosis of latent cases that are then advised to avoid exacerbating factors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/56\">",
"     56",
"    </a>",
"    ]. As an example, in a series of 112 cases in South Africa, none died during an acute attack and only one died after a protracted course [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recurrent attacks are less common in VP than AIP but are still potentially serious and life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/825/abstract/32\">",
"     32",
"    </a>",
"    ]. Risk of recurrence can be reduced by identifying and avoiding exacerbating factors such as drugs and dietary indiscretions. Long term management of hypertension and chronic renal disease contributes to better long term outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6524446\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variegate porphyria (VP) is an autosomal dominant genetic disorder of heme biosynthesis due to deficient activity of the mitochondrial enzyme protoporphyrinogen oxidase (PPO), the seventh enzyme in the heme biosynthetic pathway (",
"    <a class=\"graphic graphic_figure graphicRef68187 \" href=\"UTD.htm?24/31/25077\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26380180\">",
"    <span class=\"h2\">",
"     When to suspect variegate porphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disease is termed &ldquo;variegate&rdquo; because it can cause acute neurovisceral manifestations (eg, abdominal pain, nausea, vomiting, constipation, hypertension, peripheral neuropathy), as in the other acute hepatic porphyrias, chronic blistering lesions on sun-exposed areas of the skin, as in most cutaneous porphyrias, or both. (See",
"    <a class=\"local\" href=\"#H660099\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Neurovisceral complications of VP may be life-threatening (eg, flaccid paralysis with respiratory failure), and require treatment before an exact diagnosis has been made. Finding increased porphobilinogen in a spot urine sample in the presence of neurovisceral complaints is sufficient to initiate appropriate treatment. Spot samples of urine, plasma, and feces should be collected before treatment has begun in order to facilitate differentiation of VP from AIP and HCP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26380191\">",
"    <span class=\"h2\">",
"     Diagnosing VP",
"    </span>",
"    &nbsp;&mdash;&nbsp;VP can be diagnosed, and other porphyric conditions excluded, using a combination of urine, blood, and fecal findings, as follows. (See",
"    <a class=\"local\" href=\"#H660134\">",
"     'Laboratory findings and diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased porphobilinogen in a spot urine sample",
"     </li>",
"     <li>",
"      Increased plasma porphyrins, with a fluorescence peak at approximately 626 nm at neutral pH (",
"      <a class=\"graphic graphic_table graphicRef60572 \" href=\"UTD.htm?4/23/4477\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased fecal porphyrins with a predominance of both coproporphyrin III and protoporphyrin IX",
"     </li>",
"     <li>",
"      The diagnosis of VP can be confirmed by demonstrating reduced protoporphyrinogen oxidase activity or a genetic mutation of this enzyme. (See",
"      <a class=\"local\" href=\"#H6524401\">",
"       'Enzymatic and DNA testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26380385\">",
"    <span class=\"h2\">",
"     How to treat variegate porphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Components of initial treatment include the following, and are similar to those employed in acute intermittent porphyria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of acute intermittent porphyria\", section on 'Treatment of the acute attack'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that neurovisceral attacks accompanied by severe features (eg, pain requiring narcotics, vomiting, hyponatremia, seizures, motor neuropathy) be treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21107?source=see_link\">",
"       hemin",
"      </a>",
"      rather than glucose loading (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H5#H5\">",
"       \"Management of acute intermittent porphyria\", section on 'Intravenous hemin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that neurovisceral attacks that are less severe can be treated with intravenous or oral glucose loading (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H4#H4\">",
"       \"Management of acute intermittent porphyria\", section on 'Carbohydrate loading'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Potentially harmful drugs should be discontinued when possible (",
"      <a class=\"graphic graphic_table graphicRef57422 \" href=\"UTD.htm?42/6/43116\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Other precipitating factors (eg, inadequate intake of calories and carbohydrate, metabolic stress due to another illness, luteal phase increases in endogenous progesterone) should be recognized and addressed.",
"     </li>",
"     <li>",
"      Supportive care measures should be undertaken for other complications of VP (eg, nausea, vomiting, pain, electrolytes). (See",
"      <a class=\"local\" href=\"#H24936450\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with symptomatic VP should wear protective clothing to avoid exposure to sunlight. Affected areas should be kept clean and skin infections treated with antibiotics. (See",
"      <a class=\"local\" href=\"#H24936608\">",
"       'Treatment of cutaneous manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16215530\">",
"    <span class=\"h2\">",
"     Prevention of future attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that have contributed to past acute attacks or might precipitate future attacks should be identified and addressed. Harmful drugs should be avoided whenever possible (",
"    <a class=\"graphic graphic_table graphicRef57422 \" href=\"UTD.htm?42/6/43116\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H660165\">",
"     'Prevention of future attacks'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of acute intermittent porphyria\", section on 'Prevention of future attacks'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Meissner P, Hift RJ, Corrigall A. Variegate porphyria. In: Porphyrin Handbook Part II, Kadish KM, Smith K, Guilard R (Eds), Academic Press, San Diego 2003. p.93.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/2\">",
"      Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/3\">",
"      Kirsch RE, Meissner PN, Hift RJ. Variegate porphyria. Semin Liver Dis 1998; 18:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/4\">",
"      Eales L, Day RS, Blekkenhorst GH. The clinical and biochemical features of variegate porphyria: an analysis of 300 cases studied at Groote Schuur Hospital, Cape Town. Int J Biochem 1980; 12:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/5\">",
"      Macalpine I, Hunter R. The \"insanity\" of King George 3d: a classic case of porphyria. Br Med J 1966; 1:65.",
"     </a>",
"    </li>",
"    <li>",
"     Van der Bergh AG, Wien W. Klin Wochenschr 1937; 50:830.",
"    </li>",
"    <li>",
"     Dean G. A study of inheritance. In: The Porphyrias, 2nd ed, Pitman Medical, London 1971.",
"    </li>",
"    <li>",
"     Barnes H. Clin Proc 1945; 4:269.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/9\">",
"      DEAN G, BARNES HD. Porphyria; a South African screening experiment. Br Med J 1958; 1:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/10\">",
"      Meissner PN, Meissner DM, Sturrock ED, et al. Porphyria--the UCT experience. S Afr Med J 1987; 72:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/11\">",
"      Meissner PN, Dailey TA, Hift RJ, et al. A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 1996; 13:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/12\">",
"      Handa F, Kumar K, Kumar R. A case of variegate porphyria in an Indian. Br J Dermatol 1975; 92:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/13\">",
"      Mustajoki P. Variegate porphyria. Twelve years' experience in Finland. Q J Med 1980; 49:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/14\">",
"      Tu JB, Blackwell RQ, Feng YS. Clinical and biochemical studies of hereditary hepatic porphyria in Chinese subjects in Taiwan. Metabolism 1971; 20:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/15\">",
"      Elder GH. Hepatic porphyrias in children. J Inherit Metab Dis 1997; 20:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/16\">",
"      Brenner DA, Bloomer JR. The enzymatic defect in variegate prophyria. Studies with human cultured skin fibroblasts. N Engl J Med 1980; 302:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/17\">",
"      Timonen K, Mustajoki P, Halme H. [Porphyrias with cutaneous changes in Finland]. Duodecim 1990; 106:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/18\">",
"      Guo R, Lim CK, Peters TJ. High-performance liquid chromatographic assays for protoporphyrinogen oxidase and ferrochelatase in human leucocytes. J Chromatogr 1991; 566:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/19\">",
"      Roberts AG, Whatley SD, Daniels J, et al. Partial characterization and assignment of the gene for protoporphyrinogen oxidase and variegate porphyria to human chromosome 1q23. Hum Mol Genet 1995; 4:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/20\">",
"      Whatley SD, Puy H, Morgan RR, et al. Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am J Hum Genet 1999; 65:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/21\">",
"      von und zu Fraunberg M, Timonen K, Mustajoki P, Kauppinen R. Clinical and biochemical characteristics and genotype-phenotype correlation in Finnish variegate porphyria patients. Eur J Hum Genet 2002; 10:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/22\">",
"      Frank J, McGrath J, Lam H, et al. Homozygous variegate porphyria: identification of mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband. J Invest Dermatol 1998; 110:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/23\">",
"      Kauppinen R, Timonen K, von und zu Fraunberg M, et al. Homozygous variegate porphyria: 20 y follow-up and characterization of molecular defect. J Invest Dermatol 2001; 116:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/24\">",
"      Bonkovsky HL. Neurovisceral porphyrias: what a hematologist needs to know. Hematology Am Soc Hematol Educ Program 2005; :24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/25\">",
"      Meissner P, Adams P, Kirsch R. Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria. J Clin Invest 1993; 91:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/26\">",
"      Podvinec M, Handschin C, Looser R, Meyer UA. Identification of the xenosensors regulating human 5-aminolevulinate synthase. Proc Natl Acad Sci U S A 2004; 101:9127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/27\">",
"      Quiroz-Kendall E, Wilson FA, King LE Jr. Acute variegate porphyria following a Scarsdale Gourmet Diet. J Am Acad Dermatol 1983; 8:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/28\">",
"      Bonkovsky HL, Siao P, Roig Z, et al. Case records of the Massachusetts General Hospital. Case 20-2008. A 57-year-old woman with abdominal pain and weakness after gastric bypass surgery. N Engl J Med 2008; 358:2813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/29\">",
"      Hanneken S, Kuerten V, Hoernke M, Neumann NJ. Metastatic colon cancer triggering an acute attack of variegate porphyria. Int J Colorectal Dis 2009; 24:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/30\">",
"      Grabczynska SA, McGregor JM, Hawk JL. Late onset variegate porphyria. Clin Exp Dermatol 1996; 21:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/31\">",
"      Di Pierro E, Ventura P, Brancaleoni V, et al. Clinical, biochemical and genetic characteristics of Variegate Porphyria in Italy. Cell Mol Biol (Noisy-le-grand) 2009; 55:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/32\">",
"      Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore) 2005; 84:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/33\">",
"      Boyns AR, Cole EN, Phillips ME, et al. Plasma prolactin, GH, LH, FSH, TSH and testosterone during treatment of prostatic carcinoma with oestrogens. Eur J Cancer 1974; 10:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/34\">",
"      Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 1998; 18:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/35\">",
"      EALES L, DOWDLE EB, SAUNDERS SJ, SWEENEY GD. PRESENTATION OF PATIENTS WITH PORPHYRIA. S Afr J Lab Clin Med 1963; 14:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/36\">",
"      Mustajoki P, Vuoristo M, Reunala T. Celiac disease or dermatitis herpetiformis in three patients with porphyria. Dig Dis Sci 1981; 26:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/37\">",
"      Twaddle S, Wassif WS, Deacon AC, Peters TJ. Celiac disease in patients with variegate porphyria. Dig Dis Sci 2001; 46:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/38\">",
"      Kauppinen R, Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 1988; 57:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/39\">",
"      Germanaud J, Luthier F, Causse X, et al. A case of association between hepatocellular carcinoma and porphyria variegata. Scand J Gastroenterol 1994; 29:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/40\">",
"      Tidman MJ, Higgins EM, Elder GH, MacDonald DM. Variegate porphyria associated with hepatocellular carcinoma. Br J Dermatol 1989; 121:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/41\">",
"      Herrick AL, Moore MR, Thompson GG, et al. Cholelithiasis in patients with variegate porphyria. J Hepatol 1991; 12:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/42\">",
"      Bonkovsky HL, Barnard GF. Diagnosis of porphyric syndromes: a practical approach in the era of molecular biology. Semin Liver Dis 1998; 18:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/43\">",
"      Poh-Fitzpatrick MB. A plasma porphyrin fluorescence marker for variegate porphyria. Arch Dermatol 1980; 116:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/44\">",
"      Meissner PN, Day RS, Moore MR, et al. Protoporphyrinogen oxidase and porphobilinogen deaminase in variegate porphyria. Eur J Clin Invest 1986; 16:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/45\">",
"      Whatley SD, Mason NG, Woolf JR, et al. Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem 2009; 55:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/46\">",
"      James MF, Hift RJ. Porphyrias. Br J Anaesth 2000; 85:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/47\">",
"      Harper P, Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol 2007; 10:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/48\">",
"      Shenhav S, Gemer O, Sassoon E, Segal S. Acute intermittent porphyria precipitated by hyperemesis and metoclopramide treatment in pregnancy. Acta Obstet Gynecol Scand 1997; 76:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/49\">",
"      Poh-Fitzpatrick MB. Porphyrin-sensitized cutaneous photosensitivity: pathogenesis and treatment. Clin Dermatol 1985; 3:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/50\">",
"      Muhlbauer JE, Pathak MA, Tishler PV, Fitzpatrick TB. Variegate porphyria in New England. JAMA 1982; 247:3095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/51\">",
"      Eales L. The effects of canthaxanthin on the photocutaneous manifestations of porphyria. S Afr Med J 1978; 54:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/52\">",
"      Mathews-Roth MM, Pathak MA, Fitzpatrick TB, et al. Beta-carotene as a photoprotective agent in erythropoietic protoporphyria. Trans Assoc Am Physicians 1970; 83:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/53\">",
"      Hift RJ, Todd G, Meissner PN, Kirsch RE. Administration of oral activated charcoal in variegate porphyria results in a paradoxical clinical and biochemical deterioration. Br J Dermatol 2003; 149:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/54\">",
"      Stojeba N, Meyer C, Jeanpierre C, et al. Recovery from a variegate porphyria by a liver transplantation. Liver Transpl 2004; 10:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/55\">",
"      Medlock AE, Meissner PN, Davidson BP, et al. A mouse model for South African (R59W) variegate porphyria: construction and initial characterization. Cell Mol Biol (Noisy-le-grand) 2002; 48:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/56\">",
"      Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 1992; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/57\">",
"      Meissner PN, Harrison GG, Hift RJ. Propofol as an i.v. anaesthetic induction agent in variegate porphyria. Br J Anaesth 1991; 66:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/58\">",
"      Anderson KE. LHRH analogues for hormonal manipulation in acute intermittent porphyria. Semin Hematol 1989; 26:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/59\">",
"      Anderson KE, Spitz IM, Sassa S, et al. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med 1984; 311:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/60\">",
"      Innala E, B&auml;ckstr&ouml;m T, Bixo M, Andersson C. Evaluation of gonadotropin-releasing hormone agonist treatment for prevention of menstrual-related attacks in acute porphyria. Acta Obstet Gynecol Scand 2010; 89:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/825/abstract/61\">",
"      Schneider-Yin X, van Tuyll van Serooskerken AM, Went P, et al. Hepatocellular carcinoma in variegate porphyria: a serious complication. Acta Derm Venereol 2010; 90:512.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7126 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-84F5313BFF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_825=[""].join("\n");
var outline_f0_51_825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6524446\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H660084\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H660092\">",
"      HISTORY, PREVALENCE, AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6523550\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24936245\">",
"      Inciting events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H660099\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H660106\">",
"      Neurovisceral symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24936309\">",
"      - Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H660113\">",
"      Cutaneous symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H660120\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H660134\">",
"      LABORATORY FINDINGS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6524394\">",
"      Biochemical testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6524401\">",
"      Enzymatic and DNA testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H660142\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6524408\">",
"      Treatment of the acute attack",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24936436\">",
"      - Establishing the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24936443\">",
"      - Initial treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24936450\">",
"      - Supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24936608\">",
"      Treatment of cutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24936770\">",
"      - Acute and chronic care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24936777\">",
"      - Other treatment issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24936429\">",
"      Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H660165\">",
"      Prevention of future attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6524431\">",
"      Screening for long-term complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H660179\">",
"      Genetic testing and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H660186\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6524446\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26380180\">",
"      When to suspect variegate porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26380191\">",
"      Diagnosing VP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26380385\">",
"      How to treat variegate porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16215530\">",
"      Prevention of future attacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7126\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7126|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/12/26831\" title=\"algorithm 1\">",
"      Diagnosis acute porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7126|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/31/25077\" title=\"figure 1\">",
"      Heme synthesis and porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7126|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/26/30116\" title=\"picture 1\">",
"      Variegate porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7126|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/3/26683\" title=\"table 1\">",
"      Symptoms and signs in AIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/23/4477\" title=\"table 2\">",
"      Excretion patterns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/6/43116\" title=\"table 3\">",
"      Acute porphyrias drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/16/40198?source=related_link\">",
"      Etiology and pathogenesis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/20/3398?source=related_link\">",
"      Management of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_51_826="The role of endoscopy in biliary complications after liver transplantation";
var content_f0_51_826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The role of endoscopy in biliary complications after liver transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/51/826/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/51/826/contributors\">",
"     Andr&eacute;s C&aacute;rdenas, MD, MMSc, AGAF",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/51/826/contributors\">",
"     Karen L Krok, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/51/826/contributors\">",
"     Paul J Thuluvath, MBBS, MD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/51/826/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/51/826/contributors\">",
"     Robert S Brown, Jr, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/51/826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/51/826/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/51/826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary tract complications are an important cause of morbidity and mortality in liver transplantation (LT) recipients. The most frequent are biliary tract strictures, bile leaks, and bile duct stones. The estimated incidence of these complications ranges between 10 and 25 percent in various reports, although rates have been decreasing in recent years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Most can be managed successfully with endoscopic retrograde cholangiography (ERC) if there is a duct-to-duct anastomosis.",
"   </p>",
"   <p>",
"    This topic review focuses on the various biliary complications after LT and their endoscopic management. Reviews of other complications following liver transplantation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=see_link\">",
"     \"Long-term management of adult liver transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=see_link\">",
"     \"Infectious complications in liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary complications (bile duct strictures, leaks, and stones) following LT can be categorized as early (within four weeks) or late [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/7\">",
"     7",
"    </a>",
"    ]. Biliary strictures can be further divided into anastomotic, nonanastomotic, and diffuse intrahepatic strictures. Other complications such as bile casts, sphincter of Oddi dysfunction, mucocele, and hemobilia are rare and most also can be managed endoscopically (",
"    <a class=\"graphic graphic_table graphicRef75116 \" href=\"UTD.htm?19/5/19547\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several risk factors for the development of biliary complications after LT (",
"    <a class=\"graphic graphic_table graphicRef50456 \" href=\"UTD.htm?17/54/18283\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some studies have suggested that a major risk factor is the type of biliary reconstruction (duct-to-duct choledochocholedochostomy versus Roux-en-Y choledochojejunostomy), but it is generally agreed that the rate of complications is similar (or only marginally higher) with the Roux-en-Y technique compared with choledochocholedochostomy [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/2,8-11\">",
"       2,8-11",
"      </a>",
"      ]. Duct-to-duct anastomosis of the common bile duct has the advantage of easy access to the biliary system and preservation of the sphincter of Oddi, which in theory avoids reflux of contents into the bile duct [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Comparative studies between post-LT patients with and without T-tubes indicate that routine T-tube placement is associated with a higher incidence of biliary complications including bile leaks and cholangitis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/13-17\">",
"       13-17",
"      </a>",
"      ]. T-tubes previously were placed routinely after liver transplantation, but their role is much less apparent with more effective use of ERC.",
"     </li>",
"     <li>",
"      Risk factors for the development of biliary complications after LT (particularly strictures) are acute hepatic artery thrombosis (HAT), hepatic artery stenosis, technical factors during surgery (excessive dissection of periductal tissue during procurement, excessive use of electrocautery for biliary duct bleeding control in both donor and recipient, and tension of the duct anastomosis), small caliber of the bile duct and mismatched size between donor and recipient bile ducts,",
"      <span class=\"nowrap\">",
"       ischemia/reperfusion",
"      </span>",
"      injury, pre-LT diagnosis of cytomegalovirus (CMV) infection, donation after cardiac death (DCD), ABO blood group mismatch, older age of donor, prolonged cold and warm ischemia times, and primary sclerosing cholangitis (",
"      <a class=\"graphic graphic_table graphicRef50456 \" href=\"UTD.htm?17/54/18283\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/7,12,18-29\">",
"       7,12,18-29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;A biliary complication is usually first suspected in asymptomatic LT recipients who have elevations of serum aminotransferases, bilirubin, alkaline phosphatase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gamma-glutamyl transferase levels. Occasionally, patients have nonspecific symptoms (such as fever and anorexia), right upper quadrant abdominal pain (especially with bile leaks), pruritus, jaundice, and bile ascites. Exposure of the peritoneum and other visceral structures to bile usually results in abdominal pain. However, pain may be absent in the transplant setting because of immunosuppression and hepatic denervation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/7,11,12\">",
"     7,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial evaluation should include liver ultrasound (US) with a Doppler evaluation of the hepatic vessels (",
"    <a class=\"graphic graphic_algorithm graphicRef56381 \" href=\"UTD.htm?9/57/10143\">",
"     algorithm 1",
"    </a>",
"    ). If hepatic artery stenosis or occlusion is suspected by Doppler US, hepatic angiography is usually indicated before obtaining other tests.",
"   </p>",
"   <p>",
"    Liver biopsy is often performed to exclude rejection, although it is generally deferred in patients with biliary dilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of common bile duct stones because of the risk of causing a bile leak. In addition, histologic features of bile duct obstruction can sometimes be misleading and confused with rejection or recurrent hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, correlation of histologic findings with results of imaging tests is important. Unfortunately, abdominal US may not be sufficiently sensitive (sensitivity 38 to 66 percent) to detect biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, the absence of bile duct dilation on US should not preclude further evaluation with more sensitive techniques (see below) in patients in whom there is clinical suspicion of biliary tract complications.",
"   </p>",
"   <p>",
"    If there is a strong clinical suspicion and an US that indicates a bile duct obstruction with or without stones or a bile leak, a cholangiogram should be obtained as it is considered the reference standard for the diagnosis of biliary tract complications [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/3-7,11,12\">",
"     3-7,11,12",
"    </a>",
"    ]. Although ERC or percutaneous transhepatic cholangiography (PTC) remains the gold standard, magnetic resonance cholangiopancreatography (MRCP) has gained increasing acceptance as a reliable technique in detecting biliary complications after LT. A meta-analysis found that MRCP had a sensitivity of 96 percent and a specificity of 94 percent for diagnosing biliary obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/31\">",
"     31",
"    </a>",
"    ]. MRCP is currently considered an optimal noninvasive diagnostic tool for the assessment of biliary complications after LT (",
"    <a class=\"graphic graphic_picture graphicRef53402 \" href=\"UTD.htm?37/44/38595\">",
"     picture 1",
"    </a>",
"    ), especially if the abdominal US is normal and there is a high suspicion of a biliary complication [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37491?source=see_link\">",
"     \"Percutaneous transhepatic cholangiography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=see_link\">",
"     \"Magnetic resonance cholangiopancreatography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We generally start with an MRCP before embarking on more invasive procedures. This is particularly true when ERC",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PTC cannot be performed or there is a low probability that intervention will be required.",
"   </p>",
"   <p>",
"    In those in whom an invasive approach (ie, ERC or PTC) is required, we consider the type of biliary reconstruction, the likelihood of therapeutic intervention, and the available expertise. In our experience, ERC is perhaps the best",
"    <span class=\"nowrap\">",
"     diagnostic/therapeutic",
"    </span>",
"    intervention in patients with duct-to-duct anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/32\">",
"     32",
"    </a>",
"    ]. We generally reserve PTC for patients in whom ERC was unsuccessful and in patients with a Roux-en-Y choledochojejunostomy. In high-volume centers with experienced endoscopists, ERC can be successfully performed in patients with a Roux-en-Y choledochojejunostomy with a variable stiffness pediatric colonoscope or with deep small bowel enteroscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37831?source=see_link&amp;anchor=H1850898171#H1850898171\">",
"     \"ERCP in patients with Roux-en-Y anatomy\", section on 'ERCP using an enteroscope or pediatric colonoscope'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37831?source=see_link&amp;anchor=H1850898178#H1850898178\">",
"     \"ERCP in patients with Roux-en-Y anatomy\", section on 'ERCP using deep enteroscopy techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     BILE LEAKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile leaks occur following LT with an incidence that ranges between 2 and 25 percent (",
"    <a class=\"graphic graphic_picture graphicRef82625 \" href=\"UTD.htm?31/45/32479\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/1-7,35,36\">",
"     1-7,35,36",
"    </a>",
"    ]. The presence of a bile leak is an independent risk factor for the development of early or late strictures and requires prompt therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/24\">",
"     24",
"    </a>",
"    ]. Leakage can occur from the anastomosis, the cystic duct, the T-tube tract, or (in the case of living donor or split liver LT) from the cut surface of the liver. Many bile leaks can be resolved nonoperatively with early intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/1-7,35\">",
"     1-7,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bile leaks can be divided into early and late events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Early bile leaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early bile leaks usually occur at the anastomotic site and are often related to technical issues, not to the type of biliary reconstruction. Factors that predispose grafts to early bile leaks include lack of perfusion from the hepatic artery and other technical reasons. Bile leaks are suspected in patients with peritonitis or fluid collections seen on imaging tests. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In cases where a T-tube is in place, small anastomotic leaks can be diagnosed with a T-tube cholangiogram and be managed by leaving the tube open without further intervention. In patients without a T-tube, ERC is considered the gold standard diagnostic method in detecting bile leaks. Hepatobiliary scintigraphy (HIDA) scanning, which has a sensitivity of about 50 percent and a specificity of about 80 percent, can be helpful in cases where there is a low suspicion for a bile leak [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A biliary sphincterotomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    placement of a plastic stent in the common bile duct is successful in treating 90 to 95 percent of bile leaks. As a result, if there is a strong clinical suspicion, ERC is the treatment of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/4,5,39,40\">",
"     4,5,39,40",
"    </a>",
"    ]. In some cases small leaks can be managed with biliary sphincterotomy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/41\">",
"     41",
"    </a>",
"    ]. In contrast to postcholecystectomy leaks, where the stent can be removed in four to six weeks, in post-LT leaks we prefer the stent be left in place for approximately two to three months because of problems with delayed healing that may arise due to immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/7\">",
"     7",
"    </a>",
"    ]. Stents are not changed during this two to three month period unless there is a clinical suspicion of obstruction. At the end of this period, the leak has typically healed and no other stent is needed.",
"   </p>",
"   <p>",
"    Short-duration stenting (two to three weeks) is preferred by some experts. In our experience, two to three weeks may be too early in some patients, particularly those who are on full immunosuppression. Nevertheless, removing the stent in four to six weeks may be reasonable in patients who are clinically well and are not receiving a full immunosuppressive regimen.",
"   </p>",
"   <p>",
"    Roux-en-Y choledochojejunostomy anastomotic leaks are less common. A suspected bile leak in such patients can be diagnosed with a HIDA scan if the patient does not have a drainage catheter in place. ERC is often not feasible due to anatomic difficulties in reaching the biliary anastomosis. Management is usually performed with percutaneous internal-external drainage. Bile leaks in patients with Roux-en-Y anatomy more often require surgical management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37831?source=see_link\">",
"     \"ERCP in patients with Roux-en-Y anatomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Late bile leaks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late bile duct leaks are usually related to the removal of the T-tube, resulting from delay in T-tube tract maturation due to immunosuppression. A bile leak should be suspected in patients who develop pain when the T-tube is removed.",
"   </p>",
"   <p>",
"    ERC with placement of transpapillary stents is indicated, particularly in cases with abdominal pain and tenderness. In some cases, symptoms resolve with analgesia and without specific intervention within one week. If abdominal pain and tenderness persist and a leak is confirmed, management with ERC and placement of transpapillary stents is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/1-7,39,40,42\">",
"     1-7,39,40,42",
"    </a>",
"    ]. Surgery or a percutaneous transhepatic approach is reserved for patients in whom the endoscopic approach is unsuccessful.",
"   </p>",
"   <p>",
"    Some centers use nasobiliary tubes instead of stents. An advantage is that nasobiliary tubes permit cholangiographic followup without the need for further endoscopies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/42\">",
"     42",
"    </a>",
"    ]. However, they are often poorly tolerated and also divert bile away from the intestine, thereby decreasing the bioavailability of certain drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     BILOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with bile duct necrosis secondary to hepatic artery thrombosis, bilomas can occur due to bile duct rupture and extravasation of bile into the hepatic parenchyma or the abdominal cavity. Most post-LT bilomas occur in the perihepatic area, outside of the liver. If the biloma occurs in the hepatic parenchyma and communicates with the biliary tree, it may resolve spontaneously or, in some cases, be managed with endoscopy and a transpapillary stent. In this setting, the role of endoscopy is more diagnostic than therapeutic as disrupted bile ducts may not completely communicate with the extrahepatic ducts.",
"   </p>",
"   <p>",
"    Large bilomas not communicating with the bile ducts should be treated with percutaneous drainage and antibiotics. Surgery is indicated when the bile leak cannot be effectively controlled with nonsurgical methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     STRICTURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile duct strictures account for about 40 percent of all biliary complications after LT [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/12\">",
"     12",
"    </a>",
"    ]. The incidence in various reports ranges between 4 and 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/1-7,11,12,25,35,43-45\">",
"     1-7,11,12,25,35,43-45",
"    </a>",
"    ] with higher incidence rates seen in reports with longer follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/43\">",
"     43",
"    </a>",
"    ]. Strictures that occur early after LT are due mostly to technical problems, whereas late strictures are mainly due to vascular insufficiency, ischemia, and problems with healing and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/12,46\">",
"     12,46",
"    </a>",
"    ]. Bile leak is an independent risk factor for the development of anastomotic strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strictures can occur with either type of biliary anastomosis, although in at least two series, strictures were more common with Roux-en-Y choledochojejunostomy reconstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/2,47\">",
"     2,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strictures are classified as anastomotic or nonanastomotic, depending upon the stricture site. These two types of strictures differ in presentation, outcome, and response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anastomotic strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of anastomotic strictures (AS) occur within the first 12 months after LT (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50820 graphicRef63968 graphicRef58463 \" href=\"UTD.htm?2/4/2119\">",
"     image 1A-C",
"    </a>",
"    ). AS identified within six months after LT usually have a good response to short-term stenting (three to six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/45\">",
"     45",
"    </a>",
"    ]. However, patients require long-term surveillance since strictures often recur. In an illustrative study, patients who developed biliary strictures after LT and who initially were treated endoscopically with balloon dilation and plastic stents had a recurrence rate of 18 percent with a mean time to recurrence of 110 days [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The characteristic cholangiographic appearance of an AS is that of a thin narrowing in the area of the biliary anastomosis. In some patients, a transient narrowing of the anastomosis may become evident within the first one to two months after LT due to postoperative edema and inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/11\">",
"     11",
"    </a>",
"    ]. This type of narrowing responds to endoscopic balloon dilation and plastic stent placement; in the majority of patients, it will resolve within three months and the anastomosis will remain patent without further intervention.",
"   </p>",
"   <p>",
"    Except for the subset with this early narrowing, most patients with an AS require ongoing ERC sessions (every three months), with balloon dilation and long-term stenting (for 12 to 24 months). We place a guidewire across the stricture, dilate using balloon diameters of 6 to 8 mm, and then place 7 to 11.5 Fr plastic stents with increasing diameter and number if possible. This approach was more effective than balloon dilation alone in a study of 24 patients with AS after LT [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/49\">",
"     49",
"    </a>",
"    ]. Stents are exchanged at three-month intervals to avoid stent occlusion and bacterial cholangitis. There is some clinical experience in temporary (approximately three month) placement of covered self-expanding metal stents to reduce the need for repeated stent exchanges, but data are limited. In the published series thus far, there was a high rate of migration and stricture recurrence; however, more data are needed in order to routinely consider the use of metal stents for the treatment of AS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/50-54\">",
"     50-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients require several endoscopic interventions (mean of three to five) with long-term success rates in the range of 65 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/3,44,45,49,55-60\">",
"     3,44,45,49,55-60",
"    </a>",
"    ]. Because of these high rates of success, we suggest that endoscopic management be considered before considering percutaneous interventions or surgical repair in patients with duct-to-duct anastomosis.",
"   </p>",
"   <p>",
"    Increasing the number of stents placed may improve success rates [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/61\">",
"     61",
"    </a>",
"    ]. In a study of 83 patients with AS who were stented for a minimum of one year, up to nine 8.5 to 11.5 Fr stents were placed per ERC. ERC was repeated at 3-month intervals if only one or two stents remained, or after one year if three or more stents were in place. In addition, ERC was repeated in all patients who demonstrated signs of biliary obstruction. At the end of the study, 69 patients had reached a study endpoint (AS resolution or hepaticojejunostomy). AS resolution occurred in 65 patients (94 percent), whereas four patients (6 percent) required a hepaticojejunostomy. Treatment success was significantly associated with the total number of stents placed (mean 8.0 versus 3.5 for those who failed treatment) and the number of stents placed per ERC (mean 2.5 versus 1.3). After a median followup of 11 months, only two patients (3 percent) who had been successfully treated required repeat ERC for recurrent AS.",
"   </p>",
"   <p>",
"    In patients with Roux-en-Y choledochojejunostomy, in whom ERC is often unsuccessful, we suggest management with PTC and dilation followed by placement of a percutaneous transhepatic catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Diagnostic approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Surgical revision (usually a repair or conversion to a Roux-en-Y choledochojejunostomy) may be an alternative in stable patients with a duct-to-duct stricture that is difficult to treat. An advantage of surgery is that it eliminates the need for multiple procedures.",
"   </p>",
"   <p>",
"    As noted above, patients with bile duct strictures, irrespective of their nature, require lifelong surveillance since strictures tend to recur. The recurrence of AS is high among those patients with an initial delayed presentation (&gt;6 months) and very tight strictures. We monitor patients with periodic evaluation of liver enzymes, liver US,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MRCP, depending upon the nature and duration of the stricture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonanastomotic strictures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonanastomotic strictures (NAS) result mainly from hepatic artery thrombosis or other forms of ischemia. Less commonly they can be due to recurrence of the underlying disease such as primary sclerosing cholangitis. They account for 10 to 25 percent of all stricture complications after LT, with an incidence in the range of 0.5 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/2,6,9,43,44,63,64\">",
"     2,6,9,43,44,63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NAS can occur proximal to the anastomosis in the extra- or intrahepatic bile duct. There may be multiple strictures involving the hilum and intrahepatic ducts causing a cholangiographic appearance that resembles primary sclerosing cholangitis. Biliary sludge can accumulate proximal to the strictures leading to the formation of casts (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Casts'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/65\">",
"     65",
"    </a>",
"    ]. This may predispose the patient to develop recurrent episodes of cholangitis. NAS tend to occur earlier than AS, with a mean time to stricture development of three to six months, though they can occur up to one year following LT [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/44,63\">",
"     44,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NAS are more difficult to treat than AS. Endoscopic therapy of NAS typically consists of 4 to 6 mm balloon dilation (compared with 6 to 8 mm for AS) followed by sphincterotomy and placement of 10 to 11.5 Fr plastic stents with replacement every three months, similar to the management of AS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/44\">",
"     44",
"    </a>",
"    ]. However, time to response with NAS is more prolonged than with AS. In an illustrative study, the median time of response was 185 days for NAS versus 67 days for AS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcomes of NAS are not as favorable as AS. Only 50 percent of patients have a long-term response with endoscopic therapy with dilation and stent placement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/3-5,44,64\">",
"     3-5,44,64",
"    </a>",
"    ]. Furthermore, up to 50 percent of patients undergo retransplantation or die as a consequence of this complication despite endoscopic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/7,12,44,63\">",
"     7,12,44,63",
"    </a>",
"    ]. As a general rule, ischemic events that lead to diffuse intrahepatic bile duct strictures are associated with poor graft survival and in most instances will require retransplantation in suitable candidates.",
"   </p>",
"   <p>",
"    One of the largest series included 81 patients with NAS [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/66\">",
"     66",
"    </a>",
"    ]. Most strictures were in the extrahepatic bile duct. About one-third of the patients underwent interventional treatment (ERC, PTC, or surgery). Treatment was associated with improvement in liver enzymes, but nearly two-thirds of the patients had radiological progression despite the improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/66\">",
"     66",
"    </a>",
"    ]. Progression of NAS was more common in patients with early NAS and one or more episodes of bacterial cholangitis (which were more common in those with Roux-en-Y anatomy). Advanced fibrosis developed in 28 percent of patients. Although graft survival was compromised (73 percent at five years), patient survival was not affected. Thirteen patients (16 percent) were retransplanted.",
"   </p>",
"   <p>",
"    Surgical revision may ultimately be required in patients with strictures that are refractory to endoscopic or percutaneous treatment. A Roux-en-Y choledochojejunostomy is usually performed in patients with duct-to-duct anastomosis. In those who already have a Roux-en-Y anastomosis, repositioning the bile duct of the graft to a better vascularized area may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMMON BILE DUCT FILLING DEFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Filling defects in the bile duct after LT can be due to gallstones, sludge, blood clots, casts,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    migrated stents; most are caused by stones [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/5\">",
"     5",
"    </a>",
"    ]. Biliary stones, casts, and sludge are relatively common following LT, with an incidence between 2.5 and 12 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/3-5,9,67-69\">",
"     3-5,9,67-69",
"    </a>",
"    ]. The potential mechanisms related to the formation of casts, sludge, and stones include the presence of strictures, warm and cold ischemia, bacterial infection, and obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/7,11,35,70\">",
"     7,11,35,70",
"    </a>",
"    ]. Management is similar to the nontransplant setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stones occur late after LT (",
"    <a class=\"graphic graphic_picture graphicRef66728 \" href=\"UTD.htm?13/61/14303\">",
"     picture 3",
"    </a>",
"    ). In one series, stones appeared at a median of 19 months after LT; interestingly, following stone extraction there was a 17 percent recurrence rate within a median of six months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/3\">",
"     3",
"    </a>",
"    ]. In most cases (59 to 66 percent), one ERC session with biliary sphincterotomy was sufficient for clearance of the duct [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/3,68\">",
"     3,68",
"    </a>",
"    ]; however, two sessions were required in 24 percent, and three or more sessions were required in 17 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Casts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile duct casts are most commonly seen in the setting of ischemia (eg, HAT) when there is diffuse stricturing of the hilum [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/65\">",
"     65",
"    </a>",
"    ]. Clearance of casts may be difficult to achieve with endoscopic methods. In one series, combined endoscopic and percutaneous methods were able to successfully clear the casts in 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/65\">",
"     65",
"    </a>",
"    ]. Various combinations of sphincterotomy, balloon and basket extraction, stent placement, and lithotripsy are often necessary and many of patients will ultimately require management with PTC. Patients with Roux-en-Y choledochojejunostomy should be treated with a percutaneous method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SPHINCTER OF ODDI DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sphincter of Oddi dysfunction (SOD) has been described in 2 to 7 percent of patients who underwent LT [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The pathogenesis is unclear; one hypothesis is that denervation of the common bile duct in the ampullary region (secondary to surgical intervention) leads to the development of a hypertonic sphincter causing dilated ducts and cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/12,35\">",
"     12,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SOD should be suspected in patients with cholestasis and a uniformly dilated bile duct without filling defects; abdominal pain is not usually present. In most studies, the diagnosis of SOD was based upon clinical suspicion and the response to biliary sphincterotomy not manometry. Other causes of cholestasis or abnormal liver biochemistries (eg, rejection) should also be excluded. We suggest that patients with the above clinical features undergo biliary sphincterotomy and not manometry. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sphincter of Oddi dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=see_link\">",
"     \"Treatment of sphincter of Oddi dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     OTHER COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Miscellaneous hepatobiliary complications have been described in case series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mucocele",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mucocele is a rare complication after LT that is caused by a collection of mucus from the cells lining the cystic duct remnant, leading to extrinsic compression of the bile duct [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/71\">",
"     71",
"    </a>",
"    ]. Its formation is insidious and therefore difficult to diagnose. A computed tomographic (CT) scan or US will reveal the mucocele as a fluid collection in the region of the porta hepatis, which needs to be differentiated from other space-occupying lesions such as a hepatic artery pseudoaneurysm, biloma, loculated ascites, abscess, hematoma, or tumor. The diagnosis can be confirmed with MRCP in most patients. Endoscopic therapy is usually not recommended since most patients will require surgical or radiological drainage of the cystic duct remnant [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hemobilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemobilia can occur in patients who undergo a percutaneous liver biopsy or PTC [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/72\">",
"     72",
"    </a>",
"    ]. This condition may lead to transpapillary bleeding along with biliary obstruction due to the formation of clots. Treatment is conservative but may require angiography with embolization in patients with ongoing bleeding. Biliary obstruction can be managed with percutaneous drainage or ERC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=see_link&amp;anchor=H13#H13\">",
"     \"Uncommon causes of upper gastrointestinal bleeding in adults\", section on 'Hemobilia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bactobilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bactobilia after LT can occur without the presence of strictures, since patients who have undergone LT are predisposed to bacterial colonization of the bile ducts. In one study, bile samples were collected in 72 ERCs performed in 66 patients post-LT [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/73\">",
"     73",
"    </a>",
"    ]. Of all of the samples obtained, 73 percent were positive for microorganisms: 48 percent were gram-positive bacteria, 39 percent aerobic gram-negative bacteria, 3 percent anaerobic bacteria, and 9 percent fungi. By comparison, in a control group consisting of 68 patients with cholestasis who had not undergone LT, bactobilia was found in only 16 percent of the ERCs. Mechanical obstruction, plastic stents, gallstones, and sphincterotomy significantly increased the risk of bactobilia.",
"   </p>",
"   <p>",
"    The clinical significance of bactobilia after LT is unclear. Most patients are asymptomatic. It is possible that bactobilia is a predisposing factor for the development of some of the biliary complications that occur after LT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Biliary cast syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary cast syndrome refers to the presence of biliary casts and debris causing biliary obstruction. The etiology is not well understood. The disorder was recognized in nine patients out of 355 transplants (2.5 percent) in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/69\">",
"     69",
"    </a>",
"    ]. Patients who develop biliary cast syndrome have a poor graft survival and worse post-LT outcome compared to LT recipients without biliary cast syndrome. Several endoscopic approaches have been described with variable success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     BILIARY COMPLICATIONS AFTER LIVING DONOR LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary complications are more common in recipients who underwent adult-to-adult living donor liver transplantation (LDLT) compared with liver transplantation with deceased donors. The overall incidence of biliary complications in LDLT recipients ranges from 6 to 40 percent. Leaks may occur in up to 22 percent, and strictures occur in up to 30 percent. However, more recent data indicate that the overall incidence has steadily dropped due to better surgical technique [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25672?source=see_link\">",
"     \"Living donor liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The etiology of biliary complications in LDLT is multifactorial; risk factors include the age and sex of the recipient, the severity of the original disease, CMV infection, multiple ducts used for anastomosis, the type and methods of reconstruction, biliary leakage and ABO blood type incompatibility [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/74,76,77\">",
"     74,76,77",
"    </a>",
"    ]. Many centers perform duct-to-duct anastomosis instead of performing Roux-en-Y choledochojejunostomy, which theoretically has the advantage of a shorter operation time, no contamination by bowel contents, and a preserved sphincter of Oddi [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following illustrate the range of findings in the largest reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, early bile duct complications (bile leaks from the anastomotic site or the cut surface of the liver) occurred in 24 percent of cases; late complications (mean of 6.7 months after LT), consisting primarily of AS, occurred in 32 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/78\">",
"       78",
"      </a>",
"      ]. Early complications were managed surgically and late complications were managed with nonsurgical methods.",
"     </li>",
"     <li>",
"      In a series of 174 patients, biliary complications were managed mostly with surgical and percutaneous methods; the majority of complications were due to bile leaks and strictures [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/79\">",
"       79",
"      </a>",
"      ]. Most patients had an AS (12 patients), an AS and NAS (5 patients), or concomitant bile leaks and casts (9 patients). Twelve patients with bile duct strictures were treated successfully with ERC plus dilation with nasobiliary drainage or plastic stent placement. Five patients who failed endoscopic therapy were converted to percutaneous or surgical intervention.",
"     </li>",
"     <li>",
"      A report of 273 patients who underwent LDLT revealed a similar incidence of complications (29 percent strictures and 6 percent bile leaks) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/80\">",
"       80",
"      </a>",
"      ]. Patients were treated with endoscopy with multiple plastic stents. Success was achieved in 68 percent of biliary strictures and 50 percent of bile leaks.",
"     </li>",
"     <li>",
"      In cases of failed ERC or Roux-en-Y anatomy, percutaneous transhepatic therapy is safe and effective in managing bile leaks and strictures [",
"      <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37491?source=see_link\">",
"       \"Percutaneous transhepatic cholangiography\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the recipient, donors also experience biliary complications. The incidence ranges from 0.4 to 13.0 percent (up to 13 percent develop leaks, and up to 6 percent develop strictures) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/75\">",
"     75",
"    </a>",
"    ]. In a multicenter study that evaluated the outcome of 393 donors, bile leaks occurred in 36 patients (9 percent) and the majority of these patients required a prolonged intensive care unit stay [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/83\">",
"     83",
"    </a>",
"    ]. Biliary complications in donors are seen more often with right lobe donation and the management is the same as described for the recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25672?source=see_link\">",
"     \"Living donor liver transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF ENDOSCOPIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic therapy is generally regarded safe after LT. There is up to a 6 to 9 percent complication rate per procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/4,5,64,84\">",
"     4,5,64,84",
"    </a>",
"    ], which is not vastly different from the 5 to 8 percent complication rate seen in patients without a LT [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/85\">",
"     85",
"    </a>",
"    ]. The most common complications are pancreatitis, cholangitis, and postsphincterotomy bleeding. Other complications include bile leak, subcapsular hematoma, perforation, and stent migration. Biliary sphincterotomy, renal failure, repeated pancreatic duct injections, and therapy with mTOR inhibitors may place patients at risk for complications after ERCP [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/84,86\">",
"     84,86",
"    </a>",
"    ]. At least one procedure-related death was reported in a patient with multiple medical problems who developed severe pancreatitis after ERC and stent placement and ultimately died of ischemic necrosis of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?0/51/826/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biliary complications arising after a liver transplantation occur in 10 to 25 percent of cases, with biliary strictures, bile leaks, and bile duct stones accounting for the majority of the complications.",
"     </li>",
"     <li>",
"      Risk factors include the type of biliary reconstruction, acute hepatic artery thrombosis, hepatic artery stenosis, prolonged warm or cold ischemia, cytomegalovirus infection, ABO blood group mismatch, donation after cardiac death, and primary sclerosing cholangitis (",
"      <a class=\"graphic graphic_table graphicRef50456 \" href=\"UTD.htm?17/54/18283\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      As a general rule, a right upper quadrant ultrasound with Doppler examination of the hepatic vasculature is the first step in the evaluation of a post-liver transplantation patient with asymptomatic elevations in liver enzymes or bilirubin. If there is a strong clinical suspicion of biliary pathology, the patient should proceed directly to endoscopic retrograde cholangiography (ERC), whereas magnetic resonance cholangiopancreatography (MRCP) may be preferred if the index of suspicion for bile duct abnormalities is low. A liver biopsy may be necessary if rejection or recurrent disease is suspected. Percutaneous transhepatic cholangiography is reserved for patients with Roux-en-Y anatomy or ERC failures (",
"      <a class=\"graphic graphic_algorithm graphicRef56381 \" href=\"UTD.htm?9/57/10143\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with early or late bile leaks, we suggest ERC with placement of a plastic stent with or without sphincterotomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Stents should remain in place for two to three months to allow for healing. Surgery is reserved for leaks that do not respond to stenting. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Bile leaks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with large bilomas not communicating with the bile ducts, we suggest percutaneous drainage and antibiotics. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Biloma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with an anastomotic stricture, we suggest repeated ERC sessions with balloon dilatation (6 to 8 mm) and placement of multiple plastic stents (7 to 11.5 Fr) with routine stent changes every three months (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). An increasing number of stents (2 to 3 x 10 Fr stents) can be used at each session to achieve maximum diameter. Most patients will require between three and five sessions. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Anastomotic strictures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonanastomotic strictures are more difficult to treat than anastomotic strictures. In such patients we suggest ERC with balloon dilatation (4 to 6 mm) and stent placement (10 to 11.5 Fr) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Many patients with diffuse strictures ultimately require retransplantation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nonanastomotic strictures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with bile duct strictures, irrespective of their nature, require lifelong surveillance since strictures tend to recur. We monitor patients with periodic evaluation of liver enzymes, liver ultrasound,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      MRCP, depending upon the nature and duration of the stricture.",
"     </li>",
"     <li>",
"      In patients with common bile duct filling defects (such as gallstones, sludge, blood clots, casts, and migrated stents), we suggest ERC and sphincterotomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with suspected sphincter of Oddi dysfunction, we suggest biliary sphincterotomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Sphincter of Oddi dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/1\">",
"      Stratta RJ, Wood RP, Langnas AN, et al. Diagnosis and treatment of biliary tract complications after orthotopic liver transplantation. Surgery 1989; 106:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/2\">",
"      Greif F, Bronsther OL, Van Thiel DH, et al. The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg 1994; 219:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/3\">",
"      Rerknimitr R, Sherman S, Fogel EL, et al. Biliary tract complications after orthotopic liver transplantation with choledochocholedochostomy anastomosis: endoscopic findings and results of therapy. Gastrointest Endosc 2002; 55:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/4\">",
"      Pfau PR, Kochman ML, Lewis JD, et al. Endoscopic management of postoperative biliary complications in orthotopic liver transplantation. Gastrointest Endosc 2000; 52:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/5\">",
"      Thuluvath PJ, Atassi T, Lee J. An endoscopic approach to biliary complications following orthotopic liver transplantation. Liver Int 2003; 23:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/6\">",
"      Thethy S, Thomson BNj, Pleass H, et al. Management of biliary tract complications after orthotopic liver transplantation. Clin Transplant 2004; 18:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/7\">",
"      Thuluvath PJ, Pfau PR, Kimmey MB, Ginsberg GG. Biliary complications after liver transplantation: the role of endoscopy. Endoscopy 2005; 37:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/8\">",
"      Davidson BR, Rai R, Kurzawinski TR, et al. Prospective randomized trial of end-to-end versus side-to-side biliary reconstruction after orthotopic liver transplantation. Br J Surg 1999; 86:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/9\">",
"      Park JS, Kim MH, Lee SK, et al. Efficacy of endoscopic and percutaneous treatments for biliary complications after cadaveric and living donor liver transplantation. Gastrointest Endosc 2003; 57:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/10\">",
"      Sawyer RG, Punch JD. Incidence and management of biliary complications after 291 liver transplants following the introduction of transcystic stenting. Transplantation 1998; 66:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/11\">",
"      Verdonk RC, Buis CI, Porte RJ, Haagsma EB. Biliary complications after liver transplantation: a review. Scand J Gastroenterol Suppl 2006; :89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/12\">",
"      Pascher A, Neuhaus P. Biliary complications after deceased-donor orthotopic liver transplantation. J Hepatobiliary Pancreat Surg 2006; 13:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/13\">",
"      Scatton O, Meunier B, Cherqui D, et al. Randomized trial of choledochocholedochostomy with or without a T tube in orthotopic liver transplantation. Ann Surg 2001; 233:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/14\">",
"      Vougas V, Rela M, Gane E, et al. A prospective randomised trial of bile duct reconstruction at liver transplantation: T tube or no T tube? Transpl Int 1996; 9:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/15\">",
"      Amador A, Charco R, Marti J, et al. Cost/efficacy clinical trial about the use of T-tube in cadaveric donor liver transplant: preliminary results. Transplant Proc 2005; 37:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/16\">",
"      Koivusalo A, Isoniemi H, Salmela K, et al. Biliary complications in one hundred adult liver transplantations. Scand J Gastroenterol 1996; 31:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/17\">",
"      Sotiropoulos GC, Sgourakis G, Radtke A, et al. Orthotopic liver transplantation: T-tube or not T-tube? Systematic review and meta-analysis of results. Transplantation 2009; 87:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/18\">",
"      Sanchez-Urdazpal L, Gores GJ, Ward EM, et al. Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology 1992; 16:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/19\">",
"      Sanchez-Urdazpal L, Gores GJ, Ward EM, et al. Diagnostic features and clinical outcome of ischemic-type biliary complications after liver transplantation. Hepatology 1993; 17:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/20\">",
"      Busquets J, Figueras J, Serrano T, et al. Postreperfusion biopsies are useful in predicting complications after liver transplantation. Liver Transpl 2001; 7:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/21\">",
"      Sanchez-Urdazpal L, Batts KP, Gores GJ, et al. Increased bile duct complications in liver transplantation across the ABO barrier. Ann Surg 1993; 218:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/22\">",
"      Ludwig J, Wiesner RH, Batts KP, et al. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987; 7:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/23\">",
"      Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002; 8:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/24\">",
"      Maheshwari A, Maley W, Li Z, Thuluvath PJ. Biliary complications and outcomes of liver transplantation from donors after cardiac death. Liver Transpl 2007; 13:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/25\">",
"      Sharma S, Gurakar A, Jabbour N. Biliary strictures following liver transplantation: past, present and preventive strategies. Liver Transpl 2008; 14:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/26\">",
"      Fung JJ, Eghtesad B, Patel-Tom K. Using livers from donation after cardiac death donors--a proposal to protect the true Achilles heel. Liver Transpl 2007; 13:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/27\">",
"      Welling TH, Heidt DG, Englesbe MJ, et al. Biliary complications following liver transplantation in the model for end-stage liver disease era: effect of donor, recipient, and technical factors. Liver Transpl 2008; 14:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/28\">",
"      Dacha S, Barad A, Martin J, Levitsky J. Association of hepatic artery stenosis and biliary strictures in liver transplant recipients. Liver Transpl 2011; 17:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/29\">",
"      Jay CL, Lyuksemburg V, Ladner DP, et al. Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. Ann Surg 2011; 253:259.",
"     </a>",
"    </li>",
"    <li>",
"     Scheuer P, Lefkowitch JH. The liver in organ transplantation. In: Liver biopsy interpretation, WB Saunders, 2000. p.323.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/31\">",
"      Jorgensen JE, Waljee AK, Volk ML, et al. Is MRCP equivalent to ERCP for diagnosing biliary obstruction in orthotopic liver transplant recipients? A meta-analysis. Gastrointest Endosc 2011; 73:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/32\">",
"      Krok KL, C&aacute;rdenas A, Thuluvath PJ. Endoscopic management of biliary complications after liver transplantation. Clin Liver Dis 2010; 14:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/33\">",
"      Chahal P, Baron TH, Poterucha JJ, Rosen CB. Endoscopic retrograde cholangiography in post-orthotopic liver transplant population with Roux-en-Y biliary reconstruction. Liver Transpl 2007; 13:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/34\">",
"      Kawano Y, Mizuta K, Hishikawa S, et al. Rendezvous penetration method using double-balloon endoscopy for complete anastomosis obstruction of hepaticojejunostomy after pediatric living donor liver transplantation. Liver Transpl 2008; 14:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/35\">",
"      Scanga AE, Kowdley KV. Management of biliary complications following orthotopic liver transplantation. Curr Gastroenterol Rep 2007; 9:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/36\">",
"      Sheng R, Sammon JK, Zajko AB, Campbell WL. Bile leak after hepatic transplantation: cholangiographic features, prevalence, and clinical outcome. Radiology 1994; 192:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/37\">",
"      Banzo I, Blanco I, Guti&eacute;rrez-Mendiguch&iacute;a C, et al. Hepatobiliary scintigraphy for the diagnosis of bile leaks produced after T-tube removal in orthotopic liver transplantation. Nucl Med Commun 1998; 19:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/38\">",
"      Kanazawa A, Kubo S, Tanaka H, et al. Bile leakage after living donor liver transplantation demonstrated with hepatobiliary scan using 9mTc-PMT. Ann Nucl Med 2003; 17:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/39\">",
"      Morelli J, Mulcahy HE, Willner IR, et al. Endoscopic treatment of post-liver transplantation biliary leaks with stent placement across the leak site. Gastrointest Endosc 2001; 54:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/40\">",
"      Sherman S, Shaked A, Cryer HM, et al. Endoscopic management of biliary fistulas complicating liver transplantation and other hepatobiliary operations. Ann Surg 1993; 218:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/41\">",
"      Llach J, Bordas JM, Elizalde JI, et al. Sphincterotomy in the treatment of biliary leakage. Hepatogastroenterology 2002; 49:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/42\">",
"      Saab S, Martin P, Soliman GY, et al. Endoscopic management of biliary leaks after T-tube removal in liver transplant recipients: nasobiliary drainage versus biliary stenting. Liver Transpl 2000; 6:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/43\">",
"      Koneru B, Sterling MJ, Bahramipour PF. Bile duct strictures after liver transplantation: a changing landscape of the Achilles' heel. Liver Transpl 2006; 12:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/44\">",
"      Graziadei IW, Schwaighofer H, Koch R, et al. Long-term outcome of endoscopic treatment of biliary strictures after liver transplantation. Liver Transpl 2006; 12:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/45\">",
"      Verdonk RC, Buis CI, Porte RJ, et al. Anastomotic biliary strictures after liver transplantation: causes and consequences. Liver Transpl 2006; 12:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/46\">",
"      Testa G, Malag&ograve; M, Broelseh CE. Complications of biliary tract in liver transplantation. World J Surg 2001; 25:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/47\">",
"      O'Connor TP, Lewis WD, Jenkins RL. Biliary tract complications after liver transplantation. Arch Surg 1995; 130:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/48\">",
"      Alazmi WM, Fogel EL, Watkins JL, et al. Recurrence rate of anastomotic biliary strictures in patients who have had previous successful endoscopic therapy for anastomotic narrowing after orthotopic liver transplantation. Endoscopy 2006; 38:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/49\">",
"      Zoepf T, Maldonado-Lopez EJ, Hilgard P, et al. Balloon dilatation vs. balloon dilatation plus bile duct endoprostheses for treatment of anastomotic biliary strictures after liver transplantation. Liver Transpl 2006; 12:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/50\">",
"      Kahaleh M, Behm B, Clarke BW, et al. Temporary placement of covered self-expandable metal stents in benign biliary strictures: a new paradigm? (with video). Gastrointest Endosc 2008; 67:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/51\">",
"      Traina M, Tarantino I, Barresi L, et al. Efficacy and safety of fully covered self-expandable metallic stents in biliary complications after liver transplantation: a preliminary study. Liver Transpl 2009; 15:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/52\">",
"      Phillips MS, Bonatti H, Sauer BG, et al. Elevated stricture rate following the use of fully covered self-expandable metal biliary stents for biliary leaks following liver transplantation. Endoscopy 2011; 43:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/53\">",
"      Garc&iacute;a-Pajares F, S&aacute;nchez-Antol&iacute;n G, Pelayo SL, et al. Covered metal stents for the treatment of biliary complications after orthotopic liver transplantation. Transplant Proc 2010; 42:2966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/54\">",
"      Chaput U, Scatton O, Bichard P, et al. Temporary placement of partially covered self-expandable metal stents for anastomotic biliary strictures after liver transplantation: a prospective, multicenter study. Gastrointest Endosc 2010; 72:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/55\">",
"      Morelli J, Mulcahy HE, Willner IR, et al. Long-term outcomes for patients with post-liver transplant anastomotic biliary strictures treated by endoscopic stent placement. Gastrointest Endosc 2003; 58:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/56\">",
"      Pasha SF, Harrison ME, Das A, et al. Endoscopic treatment of anastomotic biliary strictures after deceased donor liver transplantation: outcomes after maximal stent therapy. Gastrointest Endosc 2007; 66:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/57\">",
"      Holt AP, Thorburn D, Mirza D, et al. A prospective study of standardized nonsurgical therapy in the management of biliary anastomotic strictures complicating liver transplantation. Transplantation 2007; 84:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/58\">",
"      Kulaksiz H, Weiss KH, Gotthardt D, et al. Is stenting necessary after balloon dilation of post-transplantation biliary strictures? Results of a prospective comparative study. Endoscopy 2008; 40:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/59\">",
"      Seo JK, Ryu JK, Lee SH, et al. Endoscopic treatment for biliary stricture after adult living donor liver transplantation. Liver Transpl 2009; 15:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/60\">",
"      Hsieh TH, Mekeel KL, Crowell MD, et al. Endoscopic treatment of anastomotic biliary strictures after living donor liver transplantation: outcomes after maximal stent therapy. Gastrointest Endosc 2013; 77:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/61\">",
"      Tabibian JH, Asham EH, Han S, et al. Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary strictures with maximal stent therapy (with video). Gastrointest Endosc 2010; 71:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/62\">",
"      Piardi T, Greget M, Audet M, et al. Biliary strictures after liver transplantation: is percutaneous treatment indicated? Ann Transplant 2011; 16:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/63\">",
"      Guichelaar MM, Benson JT, Malinchoc M, et al. Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am J Transplant 2003; 3:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/64\">",
"      Rizk RS, McVicar JP, Emond MJ, et al. Endoscopic management of biliary strictures in liver transplant recipients: effect on patient and graft survival. Gastrointest Endosc 1998; 47:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/65\">",
"      Verdonk RC, Buis CI, van der Jagt EJ, et al. Nonanastomotic biliary strictures after liver transplantation, part 2: Management, outcome, and risk factors for disease progression. Liver Transpl 2007; 13:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/66\">",
"      Shah JN, Haigh WG, Lee SP, et al. Biliary casts after orthotopic liver transplantation: clinical factors, treatment, biochemical analysis. Am J Gastroenterol 2003; 98:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/67\">",
"      Sheng R, Ramirez CB, Zajko AB, Campbell WL. Biliary stones and sludge in liver transplant patients: a 13-year experience. Radiology 1996; 198:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/68\">",
"      Spier BJ, Pfau PR, Lorenze KR, et al. Risk factors and outcomes in post-liver transplantation bile duct stones and casts: A case-control study. Liver Transpl 2008; 14:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/69\">",
"      Gor NV, Levy RM, Ahn J, et al. Biliary cast syndrome following liver transplantation: Predictive factors and clinical outcomes. Liver Transpl 2008; 14:1466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/70\">",
"      Cillo U, Burra P, Norberto L, D'Amico D. Bile duct stones and casts after liver transplantation: Different entities but similar prevention strategy? Liver Transpl 2008; 14:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/71\">",
"      Zajko AB, Bennett MJ, Campbell WL, Koneru B. Mucocele of the cystic duct remnant in eight liver transplant recipients: findings at cholangiography, CT, and US. Radiology 1990; 177:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/72\">",
"      Manzarbeitia C, Jonsson J, Rustgi V, et al. Management of hemobilia after liver biopsy in liver transplant recipients. Transplantation 1993; 56:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/73\">",
"      Millonig G, Buratti T, Graziadei IW, et al. Bactobilia after liver transplantation: frequency and antibiotic susceptibility. Liver Transpl 2006; 12:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/74\">",
"      Takatsuki M, Eguchi S, Kawashita Y, Kanematsu T. Biliary complications in recipients of living-donor liver transplantation. J Hepatobiliary Pancreat Surg 2006; 13:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/75\">",
"      Wang SF, Huang ZY, Chen XP. Biliary complications after living donor liver transplantation. Liver Transpl 2011; 17:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/76\">",
"      Tashiro H, Itamoto T, Sasaki T, et al. Biliary complications after duct-to-duct biliary reconstruction in living-donor liver transplantation: causes and treatment. World J Surg 2007; 31:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/77\">",
"      Lin TS, Concejero AM, Chen CL, et al. Routine microsurgical biliary reconstruction decreases early anastomotic complications in living donor liver transplantation. Liver Transpl 2009; 15:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/78\">",
"      Fondevila C, Ghobrial RM, Fuster J, et al. Biliary complications after adult living donor liver transplantation. Transplant Proc 2003; 35:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/79\">",
"      Tsujino T, Isayama H, Sugawara Y, et al. Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol 2006; 101:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/80\">",
"      Yazumi S, Yoshimoto T, Hisatsune H, et al. Endoscopic treatment of biliary complications after right-lobe living-donor liver transplantation with duct-to-duct biliary anastomosis. J Hepatobiliary Pancreat Surg 2006; 13:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/81\">",
"      Kim JH, Ko GY, Sung KB, et al. Bile leak following living donor liver transplantation: clinical efficacy of percutaneous transhepatic treatment. Liver Transpl 2008; 14:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/82\">",
"      Kim ES, Lee BJ, Won JY, et al. Percutaneous transhepatic biliary drainage may serve as a successful rescue procedure in failed cases of endoscopic therapy for a post-living donor liver transplantation biliary stricture. Gastrointest Endosc 2009; 69:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/83\">",
"      Ghobrial RM, Freise CE, Trotter JF, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008; 135:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/84\">",
"      Balderramo D, Bordas JM, Sendino O, et al. Complications after ERCP in liver transplant recipients. Gastrointest Endosc 2011; 74:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/85\">",
"      Mahnke D, Chen YK, Antillon MR, et al. A prospective study of complications of endoscopic retrograde cholangiopancreatography and endoscopic ultrasound in an ambulatory endoscopy center. Clin Gastroenterol Hepatol 2006; 4:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/51/826/abstract/86\">",
"      Balderramo D, Navasa M, Cardenas A. Current management of biliary complications after liver transplantation: emphasis on endoscopic therapy. Gastroenterol Hepatol 2011; 34:107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4596 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_826=[""].join("\n");
var outline_f0_51_826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      BILE LEAKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Early bile leaks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Late bile leaks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      BILOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      STRICTURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anastomotic strictures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonanastomotic strictures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMMON BILE DUCT FILLING DEFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Casts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SPHINCTER OF ODDI DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      OTHER COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mucocele",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hemobilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bactobilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Biliary cast syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      BILIARY COMPLICATIONS AFTER LIVING DONOR LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMPLICATIONS OF ENDOSCOPIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4596\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4596|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/57/10143\" title=\"algorithm 1\">",
"      Dx biliary obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4596|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/1/7199\" title=\"diagnostic image 1A\">",
"      CBD obstruction OLT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/11/9407\" title=\"diagnostic image 1B\">",
"      CBD obstruction dilated",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/7/13425\" title=\"diagnostic image 1C\">",
"      ERC anastomosis stricture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4596|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/44/38595\" title=\"picture 1\">",
"      MRCP biliary tract post LT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/45/32479\" title=\"picture 2\">",
"      ERCP biliary leak post LT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/61/14303\" title=\"picture 3\">",
"      Choledocholithiasis after OLT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4596|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/5/19547\" title=\"table 1\">",
"      Biliary complic post LT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/54/18283\" title=\"table 2\">",
"      Risk factors complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12874?source=related_link\">",
"      Clinical manifestations and diagnosis of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37831?source=related_link\">",
"      ERCP in patients with Roux-en-Y anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=related_link\">",
"      Infectious complications in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/4/25672?source=related_link\">",
"      Living donor liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/26/40362?source=related_link\">",
"      Long-term management of adult liver transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/51/23351?source=related_link\">",
"      Magnetic resonance cholangiopancreatography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37491?source=related_link\">",
"      Percutaneous transhepatic cholangiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29126?source=related_link\">",
"      Treatment of sphincter of Oddi dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41865?source=related_link\">",
"      Uncommon causes of upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_51_827="Clinical setting NSIP";
var content_f0_51_827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical conditions associated with nonspecific interstitial pneumonia histologic pattern",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        No detectable cause (idiopathic NSIP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Collagen vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug-induced pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immunodeficiency including HIV infection",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_827=[""].join("\n");
var outline_f0_51_827=null;
var title_f0_51_828="Confirmed autoimmune thyroid disease-associated genes";
var content_f0_51_828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F53775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F53775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Confirmed autoimmune thyroid disease-associated genes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gene symbol",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gene name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosome location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Odds ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HLA",
"       </td>",
"       <td>",
"        Major histocompatibility complex",
"       </td>",
"       <td>",
"        6p21",
"       </td>",
"       <td>",
"        2.0-4.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CTLA4",
"       </td>",
"       <td>",
"        Cytotoxic T-lymphocyte-associated protein 4",
"       </td>",
"       <td>",
"        2q33",
"       </td>",
"       <td>",
"        1.5-2.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PTPN22",
"       </td>",
"       <td>",
"        Protein tyrosine phosphatase, non-receptor type 22 (lymphoid)",
"       </td>",
"       <td>",
"        1p13",
"       </td>",
"       <td>",
"        1.4-1.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CD40",
"       </td>",
"       <td>",
"        CD40 molecule, TNF receptor superfamily member 5",
"       </td>",
"       <td>",
"        20q11",
"       </td>",
"       <td>",
"        1.3-1.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL2RA (CD25)",
"       </td>",
"       <td>",
"        Interleukin 2 receptor, alpha",
"       </td>",
"       <td>",
"        10p15",
"       </td>",
"       <td>",
"        1.1-1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FCRL3",
"       </td>",
"       <td>",
"        Fc receptor-like 3",
"       </td>",
"       <td>",
"        1q23",
"       </td>",
"       <td>",
"        1.1-1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TG",
"       </td>",
"       <td>",
"        Thyroglobulin",
"       </td>",
"       <td>",
"        8q24",
"       </td>",
"       <td>",
"        2.0-2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TSHR",
"       </td>",
"       <td>",
"        Thyroid-stimulating hormone receptor",
"       </td>",
"       <td>",
"        14q31",
"       </td>",
"       <td>",
"        1.4-2.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_828=[""].join("\n");
var outline_f0_51_828=null;
var title_f0_51_829="Complications of cough";
var content_f0_51_829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of cough",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of consciousness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rupture of subconjunctival, nasal and anal veins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dislodgement/malfunctioning of intravascular catheters",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bradyarrhythmias, tachyarrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cough syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral air embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CSF rhinorrhea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute cervical radiculopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malfunctioning ventriculoatrial shunts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stroke due to vertebral artery dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastroesophageal reflux events",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrothorax in peritoneal dialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malfunction of gastrostomy button",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splenic rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inguinal hernia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Genitourinary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urinary incontinence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inversion of bladder through urethra",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Musculoskeletal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        From asymptomatic elevations of serum creatine",
"phosphokinase to rupture of rectus abdominis muscles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rib fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary interstitial emphysema, with potential risk",
"of pneumatosis intestinalis, pneumomediastinum, pneumoperitoneum,",
"pneumoretroperitoneum, pneumothorax, subcutaneous emphysema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laryngeal trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tracheobronchial trauma (eg, bronchitis, bronchial",
"rupture)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exacerbation of asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intercostal lung herniation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Petechiae and purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disruption of surgical wounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constitutional symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lifestyle changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-consciousness, hoarseness, dizziness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fear of serious disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decrease in quality of life",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Irwin, RS, Boulet, LP, Cloutier, MM, et al. Managing a cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest 1998; 114(suppl 2):133S.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_829=[""].join("\n");
var outline_f0_51_829=null;
var title_f0_51_830="Dx vomiting children by age";
var content_f0_51_830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51919&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected causes of vomiting in the pediatric age range",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Neonate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Physiologic reflux or GERD",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pyloric Stenosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Necrotizing enterocolitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Malrotation with midgut vulvulus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hirschsprung disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital atresias, stenoses, webs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metabolic disorders",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Feeding intolerance (may be associated with cardiac, pulmonary, renal, or neuromotor disorders)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adrenal crisis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dietary protein intolerance (eg, milk protein enteritis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatobiliary disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Physiologic reflux or GERD",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anatomic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Obstruction (eg, intussusception, malrotation, Hirschsprung disease, pyloric stenosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Munchausen syndrome by proxy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infant rumination",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dietary protein intolerance (eg, milk protein induced enteritis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adrenal crisis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urinary tract infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxic ingestion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased intracranial pressure (subdural hematoma from child abuse, hydrocephalus)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatobiliary disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Childhood",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peptic ulcer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclic vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psychogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Increased intracranial pressure (tumor, hydrocephalus, subdural hematoma from child abuse)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adrenal crisis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Urinary tract infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toxic ingestion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetic ketoacidosis&nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eosinophilic esophagitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Streptococcal pharyngitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Obstruction (eg, malrotation, intussusception, incarcerated hernia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Posttussive (asthma, infection, foreign body)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatobiliary disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroparesis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Functional dyspepsia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Adolescence",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroenteritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peptic ulcer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Appendicitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psychogenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Intracranial mass",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyclic vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bulimia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pregnancy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drugs of abuse",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Suicide attempt",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eosinophilic esophagitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adrenal crisis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diabetic ketoacidosis&nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Streptococcal pharyngitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Obstruction (eg, malrotation, intussusception, incarcerated hernia)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Posttussive (asthma, infection, foreign body)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatobiliary disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastroparesis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adolescent rumination syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Functional dyspepsia",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GERD: gastroesophageal reflux disease",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_830=[""].join("\n");
var outline_f0_51_830=null;
var title_f0_51_831="Simple silicosis CXR";
var content_f0_51_831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70007&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Simple silicosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 314px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE6ARsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1TxRpKza3eTRsVkMpb2NZltFcQyYljGM9RXZ6tHu1G5z/AM9DVJoiO2RQBnRIjAblHNK9jE5Ox+fSrZgU9sH2qN4Cpz+tAFGW0ZO1ZV/ottdEl4gj/wB5RXQJM4kMbKxXbncRween1p7RpKOOD6UAea6t4bZFYFAynoQK4LVfCjeXdSk7fL5Ax96voBrYtlCoZT61zni/SlXQ7pIP9YykA+maAPmS6txyQKz5IBzwa6rVbNoJ2jdCrjjFY7wMW6UAVbC2DZ4rodPtgrKQKr2No2/BFdPpunFmXigDr/C6bo1wM129pBhR71z/AIZtPLGMdq7C3jGBxQA6GPitG2U546VAiYHSrlsvPtQBZReevFSSDAAFOjAAzgUSKTjH60ANiBGec0Srk0o+VcdfU0rg9RyKAKsqZHNZ88JOc+vHNaxGQearTgY460AYEsGMgisu9twVIroZkJzWfdR/KeKAOC1e2+VgRXB6vp4YsQPpXrOpW4YEEDNcbq9ickqM0AeXX1htPArLe0yx45rur605IK1jvZHzCQOaAMBLHcp46VIumMccV0FhZzSzeWibjjnitvTNEuLogRxZ55JHFAHI2uhtIQAmTWrF4YYjlK9V0jwp5cS4j3yHqQOK3IvCxIzIY4/1NAHhsvhUnotZ9z4WfnCH8q+io/C9qSBK7N/ujFWV8MaWoy8DP9TQB83af4LmuYZz5f3R6Vo2/hTxXDCkdrd6rHAowixzSBQPYA4r6Y0nRrKAEQWcaA+2a9AjcRxqigAAADFAFLUIw1/Pxn5zVdoSBkdPSrV4pGoXBPQuaUDpQBQMXPakaHPHarjRZOab5ax5PHNAFJ7dRgbTg9SO1RNboh5PNX3II4PFUrjG/jpQBC7jJXoT3NUbuIOhUjIPWrU/UfTrTUIcAHr/ADoA8s8b+FFnUzW64PY+lecDSmSUpKuHB5r6SurUOpBGVPUVxWveGkMvnRpk+v8ASgDzex0sFhhc89a63TtNESZIBNaum6GeCy7F966O209IwAiZPqRQBU0e2Iwdp6elb0ULcdKbBC6/eIFXlVAPvigBUjwBxViMegpkbDGMg1MvPTigCVN1OcH6mmoTUhPHWgCMZC896avK805uBnBNKhyKAGODjiqrhu5q3J0qs+CaAKzLzyBVK5gLBsCtFyoHYfWq7lCPv80Ac5e2j8/ITWDeWOcgqQfcV3Myxt/Fg1Ult92dwDD86APL9R0kOSQtYZ0lzNtVck+1euy6Ok5O0bfY1PaaBDEd0iDPpQBwXhHwtJHeieVNyngjtXolpoNtbHciAg84xwK0oLVUQAAADoBVtcIBngUAURC3QDAHYCpVtf7xwPerYdX4HFAtg5zuNAFYJCp7t9KkXk4jiH1NXIrIMSN2SBkgVOtsV4xxQAyyikON+PwFb6WkG0ZDE/Ws63hIA24Bz3rTxJ/kUAUr7/j+n/3zQDxxS33/AB/T/wC+aRKABjgVVmJbPpVmb7uBVdhQBBnHFQSDLVO2M1GRzQBUmHXioVHPFWZec1EBk8UAToN64PWo3tVYEMARU0a7eT1pWmXBxyfSgDIuYo7XLMMmsq41MKT86xoPxJrbvoftCMrH5TXJ3+mLHLl2bA7CgC/DqKSHh2IHtirMd/E5wjEkd+1cvPf29uwhiQsw6nrTk1UEAFQB0IAoA7O3mLHGR+FXIZiOhJ9jXIWd6kgBDMB9cYrXs7hsgFtw7A0AdPG4YDHepW4WqVo2Vx+NWXPygZ5NAATknmnryKgC7eS4GT39anUELQBHJ39Ky9QuRF8qctWhcyBFJ61zN7LIxbAC+9AEU95IpLOQo9TVMamgJPnKCD61S1BHd18xwFHUHvUMWlRz4aJmUk555zQB0NpepcnapUt7GtO3h3H5hxWVpelLbKC5BPXAreRvlGOKAJ0hUD+tSCMAciqhulTqcn2qSK8WTgmgBznYcAZqBsseeatMoYcfhUWznBoAWFO9XI1O4YqOFatRAZzQBYiAUY71NtyPWokO0epqaM5IJ4NAD4lAYcVeR9qgLwPTFQIOOamAIFAFG+H+mzk/3jTFFLfH/Tp/941EHPb9aACY898VE5p8p5qEnrQBE55qtuOTmp5DzUTHjigCI5NAGCGB47084UHPTvVS4lz3wtABPc5zt6Cqf2rbJ1yx7VVvrgIvLbF7msWXU8MVhyo9e5oA69ZQyZJwD2qvcxRzAgjJ7Gse0mk2owOPXceta0DpIvU5x09KAPNfFEOo291KttEApPYdR7Vyy3WqpKfNSZI15yUr3CZI2OGQEdiR0rn9SsZ9zOgEiHgtjpQByuhajM0PmXBBjJwAwwTXXadcpLjyztPoazYrfdHhlBH05rQsLfawAHymgDrbE5VQfStB8bRWdpqFYwGOQOntWi6joc0AJtBGCOnNTKPk96iRfUmp8YSgDLuu9YF9u3MzMEX3ro7pDghe9YNzYtJJ+9YBPTvQBjNDHM+OXP8Aex0rQs0hgACklh1NWJII449qpgDpUDTxxj96gA9cdaALqyJnh8fWpZJ2EfGNv161k+bG53hiqr0U9zWZqd3KsLvE2WB/hNAGo92m8qeGqH7TLFNz09a5e21eTcrXZV1PTPB/Or1rqcVyzNA+WzjY/B/D1oA7jTb5ZECu2fQ1qAB+R19a4aylAlBQsuOoJ4rq7G5xgN3oA04xirSCq6YIHvU8dAEy88VNGKhTrViPB6dRQBai5FTgcVXiyCuAMd8mp/zoAyL0/wDEwuef+WhqNG5pt8f+Jnd88bzTVPNAD3OWNQsaeT8xqFyKAIpXVSoJ+8cCjvS4BPNMnban1oAguJAOPyrIvboRn5uW9PSpry5EZx1Y/pWPNmVsn7p79zQBQ1CSSeYEEkY79KqqoXlRls9c1dvcLHliI0U9+9cne6s0byR2o8tDxuP3j/hQB073qQRgzSbT6d/yqVNVwVEJwfc9a4uwWWRpN5MpI4Hetq20yV1ilMwRjzgnNAHXw3puV2P8snb0NRPK6oQpIOagtoY0kRWZpHxxzxUyXETz+TcJjH3Wz+hoAaAkxBIKt6rVm2jaM/KAw75GKvRQxbVAAV/UVeitkyPQd6ALFmmVU44Iq66jAplpGRknp2qwyEt0oAjCjNT7flApFjO6pccUAULnCox9q5e+uG807Vzj1rsZogy4I4NYGo2S/MV49qAOZvtXFtETJtx/CO5NZD6jLKnn3AG/+BAO3rVy+sIZblnuXJK/wj+VQSrbzERZIHYnrQBV1HWbeG3UzIdxGflrKj1CK7uMwzbduCYjwSag17S5FnVhLlSCAG7VxjXbxyyRsjRMBwxH3se9AHaXJcuXniXaOmKh+xyM7SxMfKIztHBBrnYtXktLdRE5mB5Kt0A710mk6nb3MQCt5MzcBWPBoAv6VrEqOkVwPMToDn5h+Nd3Y3IIUhgy4/KuKiskM4c7VnHTHQ/WtCxlltJ/mPOenYigD0Wwn3IM5APr2rRQ5rmtOuldAVP4elb9tJuANAFxTViIjaMdKqg//WqeM8UAXIjg1PuHrVSM9Kn3UAYt+2NUu/8AroaYjc0zUm/4mt4P+mhpsbfLmgCUtyaiJpSaTHNADgMLzWffy7RkdavTNtQ1i3jfOWbv0oAzrj7xZ+vYVm3t3FApaY/P2UVPq16tsPvAyHt6Vy0yz3sxAIA7ue1ADpblrqfMjE5HyjP9Kq3emxtC0k4yP7q/1q+Yo4PkiGWAyxB5rNn1OG3QkN9odcnavQfWgC5pEZktztjMSoPvCrtosOVwS6k9c1y82p3htXR1xHMMpt+UL7U7w/ezRzSQlRInVue9AHY/2pDExiVf3qjtUH9pDl/K3HqMc/nWTGfOeTyEklcE5O3rzVqK0mW5xsZVK/MemPpQB1Gl61EwQSjafzrqLWVJgPLbI61xen6fukBlQFgOGHeuv0yMKAAMUAbcMeFqfaAM1FFnAHpVgDpQABaCKd2pD0oAikHFZt4Fxk1oS5IrNvPukUAef+KriOG4KojFyM4AriLrXIoCDP5gcHgDk1u+NbidtQn+zqcwjbnGQa8z1jUZzIJjJGLgnYy47CgDpdR1f7TdwzwzHyUGCrDjPvWfDcKzvLKo4yVUDKtXN32r3L2aWwKoGYZIXFULC+uIJmjilPmE555x+FAHZWcZlmlIgERYZLEfLtqZIE8yGeBAsMfBfruPr7Vl6b4kVwsWoQsseMgr1f6j0rbMkYjMllJmAj5h2+mKANPT9ZSJsTBtvTOckf410sUivGoJ3IRlWrz+cLLHHNERkf8ALP1rR0jVZIZdk5PlH/lmev1oA9B0qSSCUFjlT09CK7PT5Q6Ag8GuJ0uRHhT5t0bchq6bSnMbBGPB6GgDogeKlRqrIcrmnqaALiPUwfiqSHjvUyngUAZOpt/xN74dMSmmK3Bqvqtx/wAT+/UnpKRTo2yPegCyrU9CetQJmpxwKAK90/bsKxdVuBDCX43elad04AYnoK52+JnYl+E70Ac3OHnuSxYGP+I1FLJHGTyYbZOS59auajLBbKZJBsgTnjv7VxWuaxNf3Ua2qkwDpHj9aALmtapFcwS/ZJvJCcEkcv8AX2rn9JhnvJTIhdAOij7prYFhHI+7UkXzAvyqnAI96sxWreSpR44VU5HbAoAkSyBWHzZidowEH15FWmhs9PRmtIPnbqW5xWJqGrxafclNoc8fvCenvVSbXCY5pEIwc7VPINAHe6dqW+IRkgSDrswM1bs5ZTcAk7Sf73cV5nZTSSeXK08ilhwAMYrsdEneaBfNmLqDtHPIIoA9AsipcBRXR2ShQCRXJ6Azb85JUdM11UEhbGRxQBpxVOvNQQYwKnHNAC496aRTyKawyDQBXlHFYutXS2tpI54IHH1ramrjPF9wAgRlL99o70Aec6neSyaiUCnLnqenvWLqdlZyyqsqK8iHcxCjP51t31tLKzFsnHTdkfyp9jaMlu6PAuzpluTQBwOtaNazb3sZWE8a5C9Rmubg0bUYbjzXVWLDoh5NehzW0cE0rsojjAPAByTWNHK7zyNbyRsq8AJ1FAGBe3UkW2N0JvEHzHHQe9UYdYubRw6MwLHJA6N9a6C+/dTybozIrr988t71zTwtKG+xBwF/vDP60AdVYa5FflftKrbyH5RjhT/hXR/Y42CNI6iUjg5rza3RY41D4DnnBGa6/QNQh2raXbs39yUjlD6fSgDtvD16bKXypd2wnkHn8RXommyK2wBgQwyvvXm9kgyIphlh9x+xrufDzPHGIZfvDkUAdjbnMXvT4S/lgyAK+OQDxVazfK4q0x49zQBIrYqQPxVUtilEmRQBx2rXhHi7V4mPAuGArXtZCQK5PxC5HjTWh6XTV0GmS74kP50AbUX3qllJWP3NRQUXLYXigDLv3LNgfdXrWPdyqqs7/LGv61p3jgAg9K4zWL15pTHEcQr1agDL1W7kvroomzyx0Ujp71nCF43dYmVHcfe9a14RHKC3CxL1cnrWTrV/b3EElps2QleX6E0AUp7vymSKOZZ7ph97qo/xqnPeZO6WTfIF24I6Gq0Ej27RiICQID84HUVsaVp6avM0z2nlgDaWBwRQBzF7DPI0bum6EPgt61fGnXMiCO3swEBDEHgY+tdTdeTpUC2yKkhIJAPJx/jV7Q7ZZoHLuQrHJVj09qAM228NyyhRHJHGD1HcV12ieHI4V2szZPJOMCremW9tGuUcMmecHPNdBDPGSgIxntQBY06wjhRQuTgVsQxYOMUkCA7cY6Z+tXoVBPtQBJCpAAAqwBRGuB0qQLQBGRTccc4qbHFNK0AU5hxXJeILQyzqwzxXYTDFY2ogHJ9KAOLOnmSU7kBUVDfiKDaGGAOnHSt0yKsp+vWs7UFW4jO3DeuRQB5R4gW6vr25ETny+RnPAFefXyvZyvHAzm4DZBB6e9e1eItPaeB4rVvILLy+Mj8q8b1DTbq1uZElnEvln744J/CgCGPWryKJTdDzTv6n7xH1rRsdQt5Y5GQ4duqgYNc1dGUTFJo2UZzio4nIkzGdvHBoA6mINcxus20pg7eMEVFDbtbgTAF4s9M8j61mWOpLvCXTHJ4Eg5x9a7HT7JgBK7goVyoHINAHUeCrsSW6Q3J7/uyedtej6cPuhz84PBry/ToGxG8ShUHJX/CvQNAvBcRBWP71eOe4oA7azYunynaSODjODVxiQOvNZumtuHuKvufloAYz80qvxVeUgVWM+DigDivEbH/hONbA/wCfpq3NCYkFT25rnvFJK+N9bKnH+lNWx4ckLS4buOtAHXQGo71tqE5xT4e1V7w7s56CgDn9VkPlkE9epHpXI3pUglgEgTkk966PUWMrNkgKK848ZaqZibZAViTpj+I0AY3iXXWlcR2hEcCdIx1b3rJhnN3G7XJIUe/9KJbPcVkaNlIHQnr71Ql3RMxYsAvJz0A96AOk05hB5ZiKsr8BM/rWnBqc1jdqLmQbTx5UQ7Vwj6m8ij7CxVcYLDhs/wBBWlozC2kV52d5d3Rjkc0Ad3FPHqU6CGElY8sp7gehroNOslFuqRRsHLZwe9QeEoogm1WBaQAn2rr4FaF8phhjsKAKul6a9sTxtJO4r2rdtrUtcBjUUWZCHIG4da1tOQTMXBwBQBoW4IxWlCAMYqrEnIx0q5GKALUY4pwFIg4p4FACYpjDAqTqM01vSgCncdDXNa1NJHFIU6100471gaohKuduce1AHml/f6k10be3RmRuC4H3a0PKu7O0C71LbeTVDxJd3drJi2XI6ntzVXR76+1Xclyjpj+FhjigBmqakka+VJgEjBKnmuR1PS7G7kWWKX9712OcZrZ8XWgU5VguSASa4W9tZ57n5HJKnsM8fWgCG90+JfPF4wDDhQTg1ijRpvspntcOgJGM8itO+dFCIZRNjqr9R9DVmwu7cusaOVx1DDpQBzdvZlGHmj5c9CMV1Wg6i9oixuubVuqN1B9RT9RWPyvLKhu4cdR9KxrqK4s2j80NsblWI6igD0uzVlgE0DeZGeV4/nW9oisJvOTIlHLL2Nea+HL+WyuwTIZIZMZXPGK9V0ny5ESaBso3ORQB2+lSBlVh3FaUh+WsbSjhBjvzWtIeOvSgCncMVBJPFc9LcsZGIPGa19Tk2QMR2FcwZOTzQBQ8XtjxtrQXqbpq3PDy4kX/AHaxvFCZ8d60SOPtLVu6EMOuPSgDqYuAKp35+XAPJ61cTgGsy+mwGJ65wKAOQ8VyEQtDDnLfeIrg7m1dComTfz8oP8Jr0PUYwQ27lz+lcdrHlafEZbiQhc/KoPU0Ac3dx+RA0kkpEfXp39BXFatdfaJcOxSLHCjq31ra1q4uLxvMCNs7AH5VrEW08yI733ufuqBk4oAyoJo4JwULAZ5Nb9hJ+83IzMG+7u4FSaTo1vGrSXS/OhyAw4archhjRJYwGcH7gFAHqvg1FjtIZihMmMsegrtobhSuIhuz6V5hpmpyWWmRWp3O8iggdwK6LTL27mtjk+XHnn1oA7IzqBhZFGetdDoUQW33Eg7jnIrzjRy891PBMWZlOV+ma9M01PKt0UcYAoA1EXpjFWUWq0XIFXIhQBKgwKeBTZG8uJn2ltoztXqalxzQAwjmmsKlIppFAFSZeDWRfIdrVuSjism9U/NQBwWvR7QxEYb6+tcrY3NxHeBWbk/w47V3etwF4nwTmvOftE9rdTGT5lTPUdqALOvW1neIEmYmRT0Brir4TabMQuMY+U9gK2JtSt57+Tbv8zuQchazZ541mje/QNb9Mk/f96AOZktYHlaS4ZY2ZucH730rFMP2e6kbf5iL0I7VrXdpHLeSPD90ZKY5BrDErxTETEENxgUAXYdUedgkxCt0Bx1rWh82RlhusyKR1b+Vc/mNlIzlR0ccbTXS6OWaBA7h1A4I5I/+tQBLa2YgYSQruj3fd64r0DwndNHMkZH7p+v+NYGn28aKQcbum31rqtJsRCgcA4Pb+7QB3dodjLt+72rUZsn2xWFprl4gp5ZelbQz5Y+lAGJrcoS2O7jnFcq1/EGIw3HtXSeJB+6AHc1xkq/vG69aANvxKu7xtrP/AF8tWxoy4kTFZniKMnxnrB/6emrZ0dMfgKAN0krEfpiud1GYiTjnHFb0zhYGP4VyupSLGrySHCr+tAFa7kjS3Z2+ZscAd/avOfEczSTEldx7Z6D2xWnqmuN9pJ3hYxwB3FVJU+2FZGOEP60AcUILia4aKLeiOecjIBpDaeVDvdzGiEjHc11TSSQTDyiqd8kdKwtZnX7QzEq07DkMOAfWgDFvLiaS2RlOVXPbkVHpxuBeIIkkZXIzx0o8ss/7yZVfOcg9q39Nm+xWjxSuJA4OCe1AG/b2ztLGr3CQjacHOSOla/h+RXndJnkCqcMW6E1yQQ3nlwQyyB1XMZ/vV3vhnSLiC0CXSgyg7uO9AHZaBZwecHjHXmu2t0+UAAiub8OWht0XdwTya7C2UbRigCWJMYq3COeaYigVYjXmgCZRS460KKeKAI13EfOoB9jmkIqU4pjCgCCQcVm3S7gQK1HHXNU5kBzQBzeoQKynOfeuH8S6UJbZzGoUr8wOOtemXMG7PFc3rVkzptHTNAHzrqNpdW2rzOiHC8rjofaor+5keBkuFAGOE9K63x7o93Y3Ed3YswIOCg7e9cLd6h5s7+dj7QR94jhvagBunqgXfFKRzgo3aq+pWJafG0EZzgUl07LtuFhwnR8dKtQSMbKNyAfm4HfFAGa0bRDylG1O4IrU0zNtKjRsEU/xDmrRjW6aMyRZO7t0xWnZ2MCv+6THGWU8igDoPDkMe/8AevuUnOeuDXcW0eBgYridPmSKQfZ+FbqpH9K6nSNREhWFxg44P9KANu0UxXClfuGulA+SsC1A3gdRmtyFswc9aAOe8RnBRfauPlH7xvrXY+IeWB9q5CVf3jcUAdHry58Yav8A9fLVs6YmI8+tZetqD4v1b/r5atqxXCKPagCa9OIQua818ZX26drdGwq+h613+rz+XbO3fkCvNNcUKxn2lm/lQBzbWhZ1aVlJ6gZ6fWpRKkC5Vhs6kMeBUVzKkUMk7OFLdvX8K5a4u5LmV0LukfUDHH/66ANO91UTc2/zFeNw71iXLGWY70yxHUdahtnYXJWF9rnpuHFWorkx3BwVMn8Tbc0AWtN0uAus0uFiA6twBVm8tg19bxW6lodvzHGahMs14iRYCqvJPc10qzQadpsfybmfkHPP/wCqgCxo+l2drexTzTOWUAJH7/4V32lzPdSIcpt9q4C1KTNG7P8AMMN0xxW14ZuHutd3xvi1jUqFXufU0Aes6bE6hd7ZPtXRWzYAGKw9LIMQOMZrZtx0oA0YjmrMdVYuMVcioAlAp1AFKKAENNNP70hFAEEgqrIParriq0i0AU5ACKoXUSuvzCtN0qrMnJ5/CgDj9c0aO7XBUH2NfPfxC8Oz6Vqry7CYDyrDsfSvqWeMHjHWuX8S6LbapavBcRK4YdxQB836JcSXCC2cKyuCCDTRbSWF07MhMQPTPStrV/DdzoWrZXPkFiA4HQVctZIrlSk21mOByKAKQVIljaMko2C/+e1a1uEViYgCpAJPpWReMLSSRflI24I9+1RWWqCFhHLI21jliOgFAHTXDgGPytpfHDD1qbTLh1m+dmDjrmmWzW8jReSBtbtnvVsWyySko2x/Ud6AO+0Cf7Tb7mxuHB966CLiE+1cfoEn2cqrDnvXXxnKsB0IzQBja0u6NSevNclKv7xuBXaaouYee1cfOo81vrQB0usqD4t1c/8ATy1bFsNqj6Vnasv/ABVWqe9w1aDP5UTt/dWgDH1qYbfZTjHvXD63KttG7u2VPQetdPqk4MEpYgADdXlOv6ob65KIT8hIC+tAHP6/eSGcIyHB+ZTnqKwLm4uJTn5sj0NampqJAeoCjjnPPrWSUm2rtyBnGQOKACISMVyw8wngGtnT7ZollklnAkB5Wq+mWqrN5056dQ1LfXJjn3H/AFYPyg96AOj097VDHudgScuSMUanq8N1PIgOxIeAQOMVzsE9zfXkMROSx+bsAPemTNFLdi2Mm5A3Oz+KgDvNCuI72CSWRkW1CbN2cEmtjwJqEUNwbePZsb+IckHNcOShtxBA3lx5wOehrrvCEJ+2rEVAUqG3Ac0AezaZO3mKmcgd66qDkA1x+jAkpt5AwK7K0QgDPpQBdhGatxAg1BEtW0FAD8cUtFLQAlIadSYoAjcVC4qw1RsKAKrrVaZOKvOtQOOKAMuaPPas25i3ZFbcqjJzVCeMZNAHCeKNIjvIGQplv7w7GvKb+y+yNsVCrdC307V7zeQ8kY4NeZeOtLfzEnQYRT83+NAHmerPvVY5I3DIPvd/xqrBboyRyF84+VhXS3lq0siOIsqwAf3NczcwtZ3DowIDng0Aa1nfSLcgnCoMAr06d67PS4xcuro25Bzu9a4CFkDKJFYsRwSePrXYaFfi2gUMOGPIoA7O2bkEffH611OkyCS3RyzE9OewrjopF4CNnd0YV0+jvtcp2IHFAE+pD924rkZ0/etx3rsb8ZV+OormZo8yt9aANzVJD/wmGpRlTzcMc44qTWJPL058Egn+VP1Nf+Kp1Q5/5btWP4wvPselXMjdI4+mepoA5XxJfja0MbdR82Oorx3U5/IuCUbDKcDPWurTVZbiISONz5IY+9clrlsXvzJtxE/X60ARW7yXM2MbgeOTWxshigAx8wPJx0rMhc28Y8gjgY6VDJd7VMbBi5OSAc4oAuXLqS8pXcFGQme9ZCvIzefcDIySAanQupDSBhH2BNW7dYGctMhZU5GDQA1TIIJZ4ztLrsVfTNNgCWcSMF3TsMbj29afIGvJiA7LEo5XvimwKbguxGE28ADjNAFzSGZBI8kYeNxgfWvRPBp2XMCDLEjHuK5bwppKXkbtLG/lxnLtnA/CvTdFis7aRJoo1Cd+cmgD0XQ4MBT3HWuptyePaub0qYtACPlB6CuhsQMHrQBpRVZTpVaOrKdKAH0tJS0AFJ6+9LRQA00w1IaYfpQBEwqJ1qwaiagCnKvtVKZMknnp0rUdc5qpKnagDFuYwRzXK67afaIJYyu7IIxXa3ScHA5rGv4mKEqO1AHhdyk8BubfoyN8oJ5YVVvLNL+JJLgYcfKcDByK6XxtYm31KG7UcZ2t7VgWVwz3kscoDIxzyKAM+4hjix5qbgwAVgKfHdRxoFxhh0wetW9TubeMSWr/ACg/6s9ea4y+lljn+c5Q9GX0oA9G8K34e4CysfU89DXoGky/6WpzjsQa8R0C8KIdkhJPP+Ar07wrqAuIUJOZVwD7j1oA7q6GYzXOzKPMbnvXQzMJLRjwVK/nXOTEea3XrQB0WpceJdU9ftDV5/8AE/UFSyuIM/w5Ir0XWQE1zUWPXz2NeG/Ea785rrOcMSPwoA4GzvykrRE/K5z9DWvcbHs5ImGwEZBPc1xqs0bh+p7Zq7DfvcfLIcDoxzwKAEmMgcoWGMdqaha2VfNyxPI9RVmB0IeZ1yicJz1NZbb3k3Elh6+9AFhrmW+mKqMKedtaMRO0RQ8Z5J/pWWjCPPlsQRnnpRA7pu8tzvII49DQBrCfGFQ4Lck/3q2dGsGumQsCkTdfpWPpFqTcxs4JGMHHOK6uxY28bhzjd8q57CgDqLAx2FpNbLtZSBnHBAq9ZFSuEfKZBArnNNWa6DxRQyzHA+bBwxrsPD2jXgwJIfLjzwW/oKAPQvD7h4IlIO4CuytFwork9DtxBIqnO3H6111r0GKALsYxVlelVk9qsJ0oAkopKWgApqrjPJOTnk06kNAAaYacfakNADDTGp5pjUARNUMgqd6gegCjcLWReA7WArbl6msu9TrigDzrxtarLpsyvgEDI+oryK91EWe2M5II6jvXt/ixN1nNHjJKHH5V87ajlg0bHMyuSCD29KAJjqBnkkVyBMp+VvUelUg5vW8iQgDufSs/UWkjZZRxng49ans5eFlYhQetAF+KUW4KJgEcA+orqPA+s51lQf8AVqNpH864vVJwIfk4d+Vx6UzwneG3vcnIPQ0AfVFq4ksRg/w8VgTD9631qz4Tu/tGiREnJX5aiukxcSD3oA3fGM4tr/UnP/PUj86+fvFBM80jlyV3Z2kda9j+Ld0YJNRA6mVzXjkcovrPzGTgj9KAOBvk2NJkAAdD/SsxWkDA5wM/pW14k2JdDAba3IWsIH5snt0oAu+d5jrGpwicD/GtKGEeXhRuJPKnvVDRbG6v7xI7G3kmckcKM49z6V7N4S+FdzKVl1SXYWx+6i/qf8KAPJf7Nme48m3Vpi390ZxXbeFvhrrWoxLIbYRA/wAUhxgV9AeHPAul6VGvl2se71IrrYrRVACqAB0oA8g8PfCUWpWS+u9xH8MYx+tdba+A9JiYN9mDsO7c13SQD0qVbcHtQBz9rotvbqFihRQOgAqcacqkEJ0reWDA6U/yRg8UAYtvaBGDc1s24+UcU9LcelTIm2gB8Y4qdelRKDmpgOKAFFLSUtABRRSGgANNNKaYaAEao24B7+wp5ph5oAjbvUMhqZgaidDQBUk5zVC5HHPWtJ4z2qncRMQcUAcV4niLwybeu0ivmnXYmjvbhFYkKxJx9a+p9agbyJAU7elfNfiqIxalcsh+UyNlSMUAc9csrQeWzhQ3IOO9ZT3Dj7znjvmr1842RscYP+c1i3TK0paPO2gCxHK7yFhnJ4xWxpcZEiSt0DAECsK2kUsMnbz1rsdFtMQB3+YE80AezfDqbdpmzOctxXTTW/mSs3rXB+ArkQyrCeCrHIr0OQgOeaAOU+NLO+qajEp/jIrxm0vI7OR0fjd93PpXsnxSUzeJtXXkhXIA+or5+1KOe81IW9orNKW2rigCLWG/tB0NsGaXuoHf2rpfBPw01DWys1+Ht7brtx8zf4V6Z8NfANtY28Vzdx+ZOy5JcdDXrljp8cQUIoA9AKAOX8I+CrLRrZIrW3RBgZIHJ+prvLOzSFBhRmpbeAKBxVtUoAaqVKqCnqtSKtACKlSqlOVaeBQAipmneXTwKcBQAwLS7aeBzS0AMA5qaL734Uynx/eNAElFFFABSN90/SlpG+6fpQBBTadSGgBpppFPNNoAYRTCKkppHNAEDLxUEiVaYcVE4zQBlXkCtGQRkV5n4p8EWWqF2MeyQ/xLxXq9wvynismeIEnigD5b8beANS0uFmtR9ogXkBR8wFeaSBkYhl2kcFSMYr7ZvrFJkIZc15l43+G1jqxaWKPybjHDxjGfrQB86QRhnU44zzXZ6NN5KoN4245qp4h8I3/hzJuV8yAniVRwPr6Vj2VyftCw5xlhzQB6x4PmkWY3EnG9vyr1iRtzBh3AP6V5P4dwNK3qCT94V6naOr2sLHPKL29qAMz4gRZ8S6txljKf6Vy/gjwWlpdSXd0u+4kYkZH3RXo/iPTzceLr6RhmMS5/GrtnaKsmQBQBa0u0EUaqBwK3LePjOKrW0eBxWjEBQA9FwPaplFIoqRRQAqrUqimgU9aAHqKeKaO1PFADhS0gpaAFooooAKcp2mm0tAD/ADPajzPamUlAEgk9qQyZGMUykNAAaQ0vek9KAENNNOppoAaaaadSGgCNqY1Pao2OKAK8wzxVKaPk1ek71WkFAGdLGKpz24KnjmtNxzULLzigDifEujw3drJHNGrowIIIzxXzV4w8NzaDqrTRo32N2+Rv7p9K+ub+LdkYrhvFGgwanZTWkyBklH5H1oA4TwiDJocDDBDD+dej6ZIw0+3DDnYK4nTtLk0ixNmxzs+RTjrziu1eRYSI+flAH3T6UAdjquP7bu/XzmqxCowCBVbVyDrd5z1lYVbteRQBegUYq5GKrwjAq0lAD41KpgnPvUopqjvUi0AOXpT1poxT1oAcKeKaKcKAHClpBSigBaKKKAFopKKAFpKKSgBaSgUlABSE8gd6U0lACGmnqacaaaAGgEd8/WmkfNn2pxPIGeaSgBhFRtUpqNxQBA4qu4qabIBI61XwzcnigCu65PFRSMAMDrUswYHg4qldEKp+agCneN1rnZX829ULj5Tk4qXXrmTyXETkORxisrQYXRg05Jlbrk0AWdR0wXV7CVHAYSH8Ktm2Y8/L+NaqoNpIHO3aKzZ5SJWC9BxQBq6kxOvagv8A08NWja5+UiszU/8AkYdR/wCu5rUs+ooA04u1Wo6qR1ai7UATrUgqNaeOtADxT1NMXtTl60APBp30600dacKAHCnUyloAdmik70dqAFpaQUd6AFNJRSUALSd6TtSmgAJpppT1ppoADTCecUtI1ACGkofp+FMUARoAMAAcCgBSaY5460p6Uw0ARseME1E+FFPPX8Kjf7tAFSZ88Ac1QaEMSWJrQ7moJ+9AHL6ra4kBUZzVazsihMjLjb0zXQ3oG3oO1RzAbE47igCrI3lQk/3R+tclf32y7kXdjGP5V1V9/wAe5/3q871Nj/aFxyfvmgD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    There is a profusion of small rounded densities, predominantly within the upper lung zones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. E. L. Petsonk.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_51_831=[""].join("\n");
var outline_f0_51_831=null;
